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Summary
Post-menopausal osteoporosis can be a debilitating condition resulting from
increased fracture risks caused by reduced bone formation and increased
bone resorption. Two distinct classes of drugs can be used to slow down
the process of this condtiion. Anabolic drugs like parathyroid hormone
(PTH) and anti-resorptive agents (bisphosphonates) are currently available
therapies and their combined effects might be better than single therapy.
However, the advantages of prescribing a combined treatment using PTH
and bisphosphonate is still controversial. The main drawback of a combined
therapy is that the anti-resorptive agent could possibly counter the anabolic
treatment when used together.
This study was conducted to investigate the changes in bone micro-
architecture to assess the efficacy of using PTH, an anabolic drug together with
an anti-resorptive agent, ibandronate and quantify their combined influence
on trabecular bone using the rat model for osteoporosis.
Sixty female Sprague Dawley rats were subjected to either ovariectomy
(OVX) or sham surgery. Weekly subcutaneous injections of saline vehicle,
vi
vii
PTH (1-34), ibandronate or both were administered respectively, beginning
from the 4th week after OVX surgery.
Both tibias of the animals were used for ex vivo micro-CT scans, where
several micro-architectural indices like bone volume fraction (BV/TV) were
compared between treatment groups. Serum levels of bone formation and
bone resorption markers were assayed using ELISA. A one-way ANOVA was
performed to compare the changes between all groups over a period of 12
weeks.
Results from micro-architectural indices suggest that ibandronate did not
reduce PTH’s anabolic effect in the combined treatment (OVX+PTH+IBAN)
group. Serum analysis of this group showed higher (p < 0.05) levels of bone
formation markers than all other groups and lower (p < 0.01) bone resorption
markers than in the (OVX+PTH) group, indicating their additive effects at
the systemic level.
Our conclusion is that at weekly low dosages, ibandronate proved to be
more effective thah PTH for most assessments. Furthermore, a partial additive
effect was observed in this combination where a low ratio of ibandronate
is used together with PTH. We suggest that the additive effect from the
combined treatment may be dependent on the PTH to bishosphonate ratio.
This positive effect could be maximized at an optimum ratio and further
investigations may enable us to maximize the use of this combined therapy
for osteoporosis.
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Osteoporosis is a condition which affects about 75 million people in Europe,
USA and Japan and is generally characterized by increased skeletal fragility as
a result of reduced bone strength. The most severe consequences include bone
fractures from unexpected and sudden increased in load (e.g. in accidents)
which the bone is not usually accustomed to.
The condition in osteoporosis where bone strength is compromised results
from the imbalance where bone formation rate is reduced compared to resorp-
tion. For every 10% loss of bone mass, the fracture risk doubles. The rapid
loss of trabecular bone1 tissue as a result of drastic reduction in estrogen
levels after menopause (type I) is the focus of this report. The other class of
1also known as cancellous or spongy bone
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osteoporosis (type II) refers to the age-related loss of cortical and trabecular
bone in both men and women, is also applicable during the discussion of
type I osteoporosis. While type I disorder is mainly a result of a drop in
plasma estrogen concentration, type II is caused by a combination of factors:
remodeling inefficiency, insufficient nutritional level of calcium and the change
in endogenous parathyroid hormone (PTH) levels.
Osteoporosis is becoming a major health concern with the rapidly greying
population in many countries. Bone fractures from falls and accidents could
result in major costs in hospitalizations and surgery, especially for the elderly
where the chances of complete recovery is low and permanent disability is
likely.
1.2 Bone mineral density measurement
In 1994, a definition of osteoporosis based on the dual X-ray absorptiometry
(DXA) derived bone mineral density (BMD) measurement is proposed by the
several senior researchers [1, 2] in working in this area for the World Health
Organization (WHO). It is suggested that a BMD value below 2.5 standard
deviations (SD) compared to the meaurements obtained from healthy young
adult women to be considered “osteoporotic”. Skeletons of elderly women
are typically only 50 to 80% as dense as their peak at 35 years. Elderly
men’s skeleton retain 80 to 90% of their BMD at youth. The higher risk of
post-menopausal osteoporosis in women compared to men is caused by the
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rapid reduction in the female hormone, estrogen. This decline of estrogen level
following menopause results in depressed bone formation and accelerated bone
resorption. The same researchers also suggested that the BMD values that fall
below 1 to 2 SD to be diagnosed as “osteopenic”. Such classifications provide
a standard to identify individuals with their risks for potential bone fractures
where medical intervention (hormone replacement therapy, anti-resorptive
or anabolic treatments) can be prescribed to remedy the likely causes for
post-menopausal osteoporosis.
However, while easy to administer, the limitation of relying on DXA-
derived measurements is that they are planar. The three-dimensional structure
of bone is reduced to two dimensions because DXA scans from only in one
plane. BMD, measured using DXA, is therefore planar in nature. This single
BMD value, while easy for means of comparison between individuals, may
not provide sufficient evaluation of bone trabecular architecture [3]. Hence,
additional data is needed for predicting bone strength. Furthermore, studies
have shown that higher BMD measurements do not directly translate to lower
fracture risks [4, 5, 6, 7, 8, 9]. It is understandable that for most studies
that involved the ovariectomized rat as a model model for post-menopausal
osteoporosis, the severity of osteoporosis is tested at the metaphyseal region
by studying micro-architectural analysis using micro-CT [10, 11]. BMD may
not be sufficient to predict the likelihood of fractures as the micro-architecture
changes in the trabecular bone are not taken into account. Hence it could
be useful to study these micro-architectural changes in addition to BMD in
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order to understand the progress of osteoporosis and to assess the therapeutic
effects of drugs to treat osteoporosis.
1.3 Limitations of current measurement
The osteoporosis criteria based on DXA-derived BMD measurement can be
limited in a few aspects. First and foremost is that young people who have
not reached their peak bone mass (around 30 years old) will be excluded
from using this selection criteria. Fortunately, osteoporosis is not yet a
major health worry among this group of indiviudals. Another shortcoming
of using BMD is that this singular average value will not be able to account
for variation in bone size and geometry. This leads to another limitation
concerning the accuracy of using BMD as a sole indicator for likelihood of
potential fractures. While a low BMD value is a good indicator for high
fracture risks, there are false negative instances of fractures in individuals
with BMD in the normal to osteopenic range [12, 13]. Another instance of
this limitation is when postmenopausal Chinese women with significantly
lower hip BMD than Caucassian women and are classified at higher risk for
fractures initially. However, the Chinese women turned out to have fewer
fractures because their rate of bone loss and turnover rate is lower [4]. The
underlying cause for osteoporosis is high bone resorption, and low BMD
mesurement is a indicator of this condition. The strength of bone is really
dependent on its micro-architecture and the rate of remodeling.
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1.4 Available treatments
There are two main classes of drugs that are effective in mitigating bone loss in
order to delay the progress of osteoporosis. One class known as anabolic agents
like Parathyroid Hormone (PTH) has been proven to stimulate bone formation
in animal osteoporosis models [14] as well as in human clinical trials [15, 16].
Another class known as anti-resorptive agents includes bisphosphonates like
ibandronate that effectively supresses bone resorption [16, 17].
Parathyroid hormone (PTH) is a polypeptide that plays a major con-
tributing role in maintaining the balance between bone mass and calcium
homeostasis. When circulating plasma calcium concentration drops, parathy-
roid glands are stimulated to secrete PTH. The intact PTH hormone (1-84)
is cleaved in the parathyroid gland to produce the amino-terminal fragment,
PTH(1-34). The amino-terminal sequence (1-34) is required for binding to
the PTH receptors in osteoblasts in order to elicit their effects on bones.
The circulating PTH(1-34) amino-terminal fragments are constantly being
degraded by enzymes in the parathyroid gland and other organs, in order to
regulate their effects.
Although high concentration of PTH enhances osteoclastic resorption
of bone, intermittent administration of PTH produces an anabolic effect in
bones. PTH stimulates bone formation in both cortical and trabecular bone,
resulting in the increase in trabecular thickness and bone strength.
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1.5 Micro-architecture
Although BMD measurement is currently the working standard of predicting
fracture likelihood, trabecular micro-architecture can affect the overall bone
strength to a large extent.
The idea about the relationship between trabecular micro-architectural
pattern and bone strength has a long history since Hermann von Meyer,
an anatomist and Karl Culmann, an engineer, observed that the trabeculae
struts in the femur are arranged along directions of maximum compression
and tension stresses similar to the structure of a Fairbank crane. This
arrangement ensures maximum strength with the available bone material.
From their results, Julius Wolff based his theory on the similarity of trabecular
pattern and maximum stress which is the main idea in Wolff’s law. In the
case of osteoporisis, the compressive trabeculae become thicker while those in
other orientations become thinner or disappear. The Singh index [18] provides
6 grades of osteoporosis severity by comparing trabecular pattern in x-rays
images with standard charts. Grade 6 refers to normal individuals, grade 3
points to established osteoporosis and grade 1 refers to severe osteoporosis.
The only drawback of this method is that it may not be quantitatively accurate
as two-dimensional x-rays images are used.
Currently, micro-architecture of trabecular can be measured by several
histomorphological indicators like the number of trabeculae defined in a given
1.5. MICRO-ARCHITECTURE 7
volume (Tb.N)2, their mean thickness (Tb.Th) and their average separation
distance (Tb.Sp). The spatial distribution of trabecular tissue can be described
by its porosity (Tb.Po), its three-dimensional volume (BV/TV) and its
total surface area to volume ratio (BS/BV). An indication of the overall
shape of each trabeculae (either more plate-like or rod-like) is measured
by its structure model index (SMI) [19]. In the past, evaluation of these
histomorphological indices was done using two-dimensional histomorphometry.
With the increase in computing power, modern imaging modalities like micro-
computed tomography (micro-CT) has enabled routine three-dimensional
measurements for both excised bone tissues as well as for in vivo conditions
in high resolutions.
It is also feasible to employ micro-CT analysis to evaluate the effectiveness
of current drugs against osteoporosis. Ibandronate has been proven to be
more potent than other bisphosphonates in animal experiments [20, 21, 22] to
reduce bone resorption at lower dosages compared to other bisphosphonates.
Parathyroid hormone is currently available for increasing the rate of bone
formation. Both classes of drugs uses different mechanisms to delay the
undesirable effects of osteoporosis. However, there is little documentation
about the morphological changes in the trabecular bone following these drug
treatments. Therefore this study was carried out to investigate the differences
between PTH’s anabolic effect and ibandronate’s anti-resorptive effect on
micro-architectural changes following the onset of osteoporosis. It addresses
2More details about these indices in chapter 2, section 2.15 to section 2.22
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the changes in morphological indices in the ovariectomized (OVX) rat as a
model for osteoporosis and investigates the changes under the influence of
PTH or ibandronate.
Just as we must not overlook the whole forest for the trees, it is important
not to forget the fact that micro-architecture is the combined result from the
direction of weight bearing as well as bone turnover, contributed by bone
formation and resorption. Data is accumulating that bone turnover markers
may also complement the assessment for bone strength [5].
1.6 Scientific questions
Especially for the rapidly greying population, osteoporosis continues to be
a medical challenge. It is a condition that leads to pain and higher risk of
fracture due to the reduction in bone strength and stability [38, 39, 2].
The most common strategies used to mitigate the effects of osteoporosis
include 2 distinct classes of drugs: both the anabolic parathyroid hormone
(PTH) and anti-resorptive bisphonates (BP) are effective when used individu-
ally even though their mechanisms of action differs.
Administration of PTH has been studied and found to have anabolic effect
on bone structural properties in mouse models [40] and human clinical trials
using alendronate and PTH (1-84) [15, 16]. PTH increases bone formation,
eventually increasing bone volume and strength. An alternative is to employ
the use of bisphonates (e.g. ibandronate or zolendronate), which have been
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successfully shown to reduce fracture incidences by suppressing bone resorption
[17, 41, 42, 43]. The bisphonate – ibandronate, has shown to be effective
in inhibiting resorption in rats [20] and ovariohysterectomized dogs [21, 22].
With the administration of long-term treatment with ibandronate, bone
volume, bone strength and micro-architecture were restored [44].
There are still controversies involved in the merits of using both BP and
PTH to produce an additive effect [15, 45, 46, 47, 48, 49]. One school of
thought suggests that a combined administration of the full intact hormone,
PTH (1-84) and alendronate has no significant synergistic effect on post-
menopausal women when measuring their bone mineral density (BMD) and
changes in biomarkers [15]. However, BMD measurment alone does not take
into acount the fine trabecular architecture [19] and bone stiffness. Moreover,
there are increasing evidences showing that a high BMD measurement does
not always correlate to a lower fracture risk [4, 5, 6, 7]. A recent study done
on C57BL/6 mice found that the combined therapy using alendronate and
the truncated PTH (1-34) is synergistic in the lumbar vertebra and additive
in the femur [48].
1.7 Aim
Our current aim is to assess the net advantages of combining PTH (1-34)
with with a bisphosphonate, ibandronate, and whether there is an optimal
ratio between the 2 drugs to reverse the effects of osteoporosis.
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In this study, we are looking into the net additive advantage of the anabolic
PTH with anti-resorptive ibandronate using the established OVX rat model.
Micro-architectural [28] changes and biomarkers for bone formation and
resorption were assessed between sham or ovariectomized animals administered
a single drug or a combination of both drugs. Weekly administaration of
low dosages of PTH and ibandronate were used to reduce the undesirable
side effects present in higher dosages [44, 50, 51]. To evaluate the efficacy of
the combined treatment, micro-architectural changes and biomarkers were





Until recently, histological staining and microscope measurement methods
were used to quantify bone loss from osteoporosis. Although these methods can
provide an indication regarding the effects of bone modeling and remodeling,
they are limited to a few two-dimensional bone cross-sections. Another
limitation of these methods is that an assumption of plate-like [23] trabecular
structures had to be assumed.
In recent years, micro-computed tomography (micro-CT) is becoming the
more preferred quantitative method to investigate bone micro-architectural
changes in laboratory animals in genetic studies or drug trials. The advantages
of using an imaging modality based on three-dimensional acquisition of x-
rays attenuation include high resolution images, relatively short scan times,
11
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three-dimensional rendering capabilities and non-destructive analysis of bone
micro-architecture and strength.
2.2 Resolution
Higher resolution from micro-CT scans provides the visualization of micro-
scopic details. The higher the resolution, the lower the inter-pixel distances.
Typical resolutions can range from 14 µm to 36 µm. Image resolutions at this
range will be sufficient to elucidate the fine rod and plate structures of the
trabecular bone, where the thinnest sturctures could measure between 30 µm
to 50 µm. Inter-pixel distances in three-dimensional space can be converted
to voxel space. Usually when reporting results where micro-CT is applicable,
voxel size is preferred over resolution [24].
Figure 2.1 shows the rendering using 14 µm voxel size to illustrate the
effects of steroid-induced osteoporosis in mice. The region of interest (ROI)
is located at the distal metaphysis. The effects of glucocorticoid (a steroid
to suppress the immune system) at high concentration (left) versus normal
(right) is easily visible.
To achieve accurate rendering and analysis from the images obtained from
a scanned bone sample, it will be useful to consider carefully several factors
beforehand. The factors include: sample preparation, type of surrounding
medium, voxel size (resolution) of the image needed, region of interest for
segmentation and the type of indices for mrophological analysis.
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(a) High steroid administration (b) Normal
Fig. 2.1: Effects on trabecular bone by (a) High steroids levels com-
pared to (b) Normal levels
2.3 Experimental design
This study investigated the effects of ovariectomy-induced osteoporosis and
the efficacy of combining PTH (anabolic) and ibandronate (anti-resorptive)
treatemnts. By using the well-established rat OVX model, changes in trabec-
ular bone and the effectiveness of a combined therapy were evaluated using
micro-CT analyses.
The experimental control (SHAM) group served to identify any bone
growth over the course of the experiment. The untreated (OVX+VEH) group
administered with saline vehicle served as the placebo group to determine
the time when each treatment caused a significant improvement from the
osteoporotic condition. Since the difference between OVX and SHAM have
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already been well-established from previous studies using micro-CT, fewer
animals (2 animals per time point) were allocated to SHAM and OVX groups
in this study. For most of the indices measured, standard deviations of SHAM
and OVX+VEH were no larger than other groups. Nevertheless, the limited
number of animals used per time point made it difficult to establish significant
differencess in some indices.
In this study, relatively young rats (12 weeks old) were used. Nevertheless,
There have been studies done using 3-months-old (12 weeks) rats to investigate
the effects of estrogen, testosterone and raloxifene in fracture healing during
early osteoporosis. Furthermore, the effects of vibrational stimulation to
prevent bone loss in the OVX model were thoroughly investigated using
3-months old rats [54, 55, 56]. Unlike the rabbit osteoporosis model [36], even
the skeletons of aged rats (3 months old) do not achieve full skeletal maturity
and have very low rates of remodelling in the cortical bone.
2.4 Animals
This section is included for the sole reason that the reader has some idea
about the origin of the animals involved and the treatments given prior to
obtaining the tibia sample for micro-CT scans1.
Sixty female rats from the Sprague Dawley stock were purchased from
the NUS Centre for Animal Resources and housed in the Animal Holding
1The author of this manuscript had little contribution in this section, and shamelessly
left the most laborious part of the work to other researchers in the group
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Unit (AHU). They were maintained at a room with temperature of 23 ◦C and
controlled 12:12-hour light:dark cycle for regular circadian rhythm. They were
kept in groups of 2 animals per cage and provided with standard rodent chow
(Harland, Model T.2018S) and water ad libitum. The animals were subjected
to either OVX or sham surgery following one week of acclimatization after
arrival to AHU. All procedures were kept in accordance with the protocol
from the NUS Instutional Animal Care and Use Committee.
Ovariectomized (OVX) rats have their levels of estrogen greatly reduced
from the removal of the ovary glands and are established animal models for
osteoporosis. In this study, female rats from the Sprague Dawley stock of age
6 to 8 weeks were either subjected to OVX or sham surgery.
The group of rats that underwent sham surgeries were subjected to
identical surgical procedures as their counterparts in the OVX groups. The
only difference in surgical protocol is that their ovaries are left intact. This
group of rats served as the control group.
Those rats with their ovaries removed were divided into groups and were
administered either with saline vehicle (VEH), parathyroid hormone2 (PTH)
or ibandronate3 (IBAN). They were eventually divided into five study roups:
SHAM, OVX+VEH, OVX+PTH, OVX+IBAN and OVX+PTH+IBAN.
0.9% saline (vehicle) was used to dilute PTH (1-34) from Sigma-Aldrich,
Singapore and ibandronate from Roche Diagnostics GmbH, Mannheim, Ger-
2anabolic therapy
3anti-resorptive therapy
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many. Animals in the PTH group received subcutaneous injections of PTH
(10 µg/kg body weight) every week, beginning from the fourth week after
OVX surgery, Similarly, the IBAN group received ibandronate (7 µg/kg body
weight) administered subcutaneously at the same frequency at fourth week
post surgery. The PTH+IBAN group received both treatments while the
OVX group was given only the saline vehicle.
2.5 Anabolic or anti-resorptive treatment
Twenty-five out of the total sixty animals were allocated to evalaute the use of
either anabolic or anti-resorptive treatment. Three animals were sacrificed at
the start of the experiment (day 0) to serve as baseline control. Subsequently,
two animals from the SHAM group and three each from the OVX, PTH and
IBAN groups were euthanized at week 6 and 12.
The experiment ended at the 12th week when the animals were sacrificed
and their right tibias harvested. The bones were wrapped in phosphate
buffer saline-soaked gauze and stored at −20 ◦C until they are thawed to be
subjected to ex-vivo micro-CT scans.
2.6 Combining anabolics and anti-resorptives
The main experiment included all sixty female SD rats that were subjected
to either OVX or sham surgery and randomly divided into 5 groups: (SHAM,
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OVX+VEH, OVX+PTH, OVX+IBAN and OVX+PTH+IBAN). Drug admin-
istration were carried out weekly with saline vehicle (0.9% NaCl), parathyroid
hormone (PTH) [50], ibandronate (IBAN) [51] or both drugs accordingly. At
every 2 weeks, two animals from the SHAM and OVX+VEH group and three
animals from each treatment groups were euthanized using CO2. The excised
left and right tibias were cleaned of the soft tissues and the bones wrapped
in PBS-soaked gauze and stored at −20 ◦C. Previous studies of fractures
in rat bones have been focused on the metaphyseal region of long bones
where reduction in trabecular bone occurred was most severe [10]. Hence,
the trabecular-rich metaphysis is a suitable region to study the progression of
osteoporosis using morphological analysis in the ovariectomized rat model.
2.7 Sample
The soft tissue, like skin, muscles, tendons and ligaments should be removed
as cleanly as possible from the bone sample if ex-vivo scans are intended.
This will ensure that only the hard calcified tissues like bones are present
during segmentation at a later stage.
It is a common practice to freeze the bone sample to prevent its degradation
after harvesting from the sacrificed animal. This is necessary to preserve
the material properties of the bone for mechanical tests after scanning is
completed. The sample can be maintained at −20 ◦C with gauze soaked in
phosphate buffer saline. It is possible for the gauze-wrapped bone sample to
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be scanned wihtout affecting the attenuation of the x-rays.
An important question will be whether deep-freezing and thawing will
destroy the structural integrity of fine trabecular bone. Other investigators
have demonstrated that freezing at −20 ◦C or −70 ◦C completely preserves the
compressive modulus and strength of trabecular bone [25]. When TiAl6V44
rods were implanted into the intermedullary space, mechanical pull tests
showed no significant difference between fresh and frozen-thawed (−20 ◦C)
bone/implant in rat tibias [26], implying that the structural integrity of
trabecular bone stays intact.
While extreme low temperature causes no lasting effect to trabecular bone,
boiling or autoclaving on the other hand, reduces the trabecular’s compressive
strength by 26% and its compressive modulus by 59% [25]. Sterilization by
autoclave should not be applied if mechanical tests are to be used subsequently.
Data acquisition from 360 ◦ around the long axis of the bone sample is
required in order to provide a three-dimensional rendering of the region of
interest for further analysis. With the sample positioned in between the
x-rays source and detector, there are two ways to accomplish this. The bone
sample has to either rotate on its long axis or the x-rays source and detector
revolve perpendicularly to this axis. The Shimadzu scanner uses the first
method while the Skyscan machine uses the second. It is important that
the bone samples are secured in their positions during rotation as vibrations
will ultimately produce blurred images and undesirable artifacts in the data.
4Titanium-Aluminium-Vanadium alloy
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These undesriable artifacts are impossible to remove during image processing
and will impede the segmentation and analysis process.
To minimize vibrations in the bone sample during scan, low density foam
[24] or low attenuating plasticine can be used to secure the sample in place.
The use of such materials with low x-rays attenuation is necessary to ensure
most attenuation of the x-rays is due to the bone in order for the acquired
image to have high contrast between tissue and non-tissue. Materials with
similar x-rays attenuation coefficients to bone tissue should be avoided near
the bone.
There are situations materials with high x-rays attenuation coefficients
can be useful. Phantoms of known densities can be used during scans where
they provide information relating intensites in the acquired image to standard
densities. Bone mineral density (BMD) and content (BMC) can be calculated
from this relationship. The need for indentifying multiple bone samples in
the same scan is another situation that requires such materials as “markers”.
As far as we know, there has not been any published articles that reported
inceasing the number of sample resulted in less volume registered due to more
x-rays attenuation. More than one bone sample can be scanned at the same
time. At a voxel size of 16 µm, the field of vision (FOV)5 of the scan can
occupy two rat tibias positioned vertically or six positioned horizontally.
5FOV defines the area for data acquisition
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2.8 Tibia scan
The excised right tibia was ex-vivo scanned in the proximal metaphyseal
region in an upright position using a SMX-100CT scanner (Shimadzu, Kyoto
Japan). The source to object distance (SOD) is 41 mm and source to image
(SID) distance is 339 mm [52]. A volume of interest (VOI) contained 200
CT slices was obtained beginning from 1 mm distal to the proximal growth
plate [28]. The dataset obtained had an isotropic voxel size of 16.47 µm from
cone-beam reconstruction (46 kV, 49 µA, with 3 times image averaging to
remove noise).
A region of interest, 3.63 mm thick, was measured starting from 1 mm
distal to the tibia growth plate. A total of 220 micro-CT slices was acquired
for each tibia.
A semi-automatic contouring method was used to isolate the trabecular
region in the images for morphological analysis. The grayscale datasets were
segmented using a global threshold (28% of the maximal grayscale value) to
form binary images for analysis of trabecular architecture.
An alernative method, dual threshold technique [30], can be used for
segmentation of trabecular region from the cortical bone. The grayscale
dataset was segmented using a fixed global threshold [24] of a percentage
of the maximal grayscale value [10]. Quantitative analysis [53] using the
CT Analyzer program (Skyscan, Phil Salmon) was used to evaluate bone
volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular separa-
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Fig. 2.2: Region of interest for rat tibia
tion (Tb.Sp), trabecular number (Tb.N), structure model index (SMI) and
trabecular porosity (Tb.Po) in the same VOI.
Measurements obtained at different time points (0 to 12 weeks after
surgery) and treatment groups (SHAM, OVX+VEH, OVX+PTH, OVX+IBAN)
were analyzed.
The region of interest in the rat tibia is shown in Fig 2.2. This region
selected [10] is measured starting from 1 mm distal to the tibial growth plate.
Having the voxel size of 16.5 µm multiplied by 220 micro-CT slices, the total
height of this region is 3.63 mm. Analysis is done on the trabecular region
excluding the cortical bone as most changes occur in this region [10] at the
onset of osteoporosis.
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2.9 Medium
Even though the bone sample can be immersed in various fluid media during
scans, it is advisable to employ a standard medium so that comparison among
samples is possible without regard to the type of medium used. Various
common media include water, phosphate buffer saline solution or just air. If
the sample is immersed in a liquid medium, the holding vessel (most likely an
eppendorf or falcon tube) will also contribute to the total x-rays attenuation.
Of various media used, air has the lowest x-rays attenuation coefficient.
Scanning without any surrounding media will result in images that provide
highest contrast. This makes segmentation easier when identifying bone from
other non-bone tissue. The drawback of employing air as the surrounding
medium is that bone surface can dry up rapidly, espacially during longer
scanning times required for higher resolutions. Bone samples that are exposed
to air during the scanning process have to be re-immersed in saline solution
as soon as the scans are completed. This is to prevent any material property
changes to the bone matrix. Viscosity, η, a material property of bone, is
directly related to its water content and it indicates how much damping force
the bone can provide before breaking.
2.10 Voxel
A typical micro-CT scan is capable of generating a dataset of hundreds of
sequential cross-sectional images within the region of interest defined by the
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user. Higher resolution generally means that the voxel size is smaller. The
pitch or distance between adjacent images within a dataset is equivalent to the
inter-pixel distance. In this way, a voxel, which is formed by the coordinates
of the pixels, will be isotropic. The dimensions of a voxel, which can be
considered the smallest bone unit, will be equidistant in three dimensions.
The minimum voxel size should preferably be 18 µm or lesser in order to
elucidate the fine trabecular struts. If the region of interest consists of only
cortical bone (e.g. in the mid-diaphysis6), a voxel size of 36 µm would
probably suffice. In theory, the highest resolution (smallest voxel size) should
be preferred. However, higher resolutions require exponentially longer image
acquisition time. The resultant dataset generated will also be larger in size
compared to using lower resolutions. This equates to longer computational
time and memory required to load the dataset for rendering and analysis.
Eventually, a trade-off between resolution and processing time will converge
to an optimal voxel size about 10 to 20 µm for trabecular tissue.
2.11 Segmentation
Datasets consisting of grayscale images are produced after the micro-CT scans.
Segmentation is an image processing technique used to identify bone tissue
from the surrounding region. This process is an important step that produces
a binary image before other image processing and morphological analysis can
6midshaft of bone has only thick cortical and no trabecular bone
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be carried out. The simplest way is to decide on a global threshold value for
segmentation [24]. Each pixel in the dataset is represented by an unsigned
integer (8 bits) holding gray intensity levels from 0 (black) to 255 (white).
(a) 256 gray levels (b) 64 gray levels
(c) 16 gray levels (d) 4 gray levels
Fig. 2.3: Micro-CT image with (a) 256, (b) 64, (c) 16 and (d) 4 gray
levels
A concern was raised concerning whether 256 gray levels will be sufficient
or more levels will lead to better segmentation to elucidate the fine details
in trabecular bone. Fig 2.3 shows the same micro-CT image from 256 gray
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levels to 4 gray levels. As the human eye cannot easily differentiate more
than 60 levels of gray, it is apparent that there is no discernable difference
between 256 and 64 gray levels as shown in Fig. 2.3 (a) and (b). However
in the extreme case where only 4 gray levels are used in Fig. 2.3 (d), much
details are lost.
At segmentation, integers with gray levels above the cut-off threshold will
be converted to binary 1 (true) while those below the cut-off will be converted
to binary 0 (false). An inappropriate threshold value will lead to systematic
under or over-estimates during morphological analysis.
It is necessary to compare the segmented image to the original grayscale
image, to ensure that the optimum threshold is indeed selected. The selected
threshold will be then be used as the fixed global threshold threshold be-
tween all datasets, where comparison between different bone samples can be
performed during analysis.
2.12 Region of Interest
The Region Of Interest (ROI) or Volume Of Interest (VOI), determines
the volume where the morphological analysis is to be performed. Either
semi-contouring [10, 27, 28] or automatic contouring [29, 30] methods can be
employed to define this region. The drawback of the semi-contouring method
is that it is dependent on the user’s judgement and the region can vary among
users. The automatic contouring method employs two thresholds as inputs
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to differentiate the cortical and trabecular region for all the images in the
dataset performed by a script. This automatic dual threshold method has
been reported to be applicable to mouse, rat and human tibias [30].
Studies done by researchers in this field have shown that most drastic
changes in bone micro-architecture occur in the trabecular region within 8 to
12 weeks after ovariectomy [28, 10, 31]. Most of the discussion that follows
will be based on the morphological analysis in trabecular part of the tibia and
femur as it is the first region to exhibit signs of bone loss where formation is
superseded by resorption.
2.13 Rendering of bone volume
The typical steps involved in the rendering of a 3D volume from the segmented
dataset involved the use of isosurface and isocap.
Fig 2.4 illustrates the steps involved in rendering done on both cortical
and trabecular regions. The gray scale image is acquired after micro-CT scan
(step 1). Segmentation with an apporpriate threshold level is achieved in
step 2, which is assessed by comparing with step 1. Using a semi-contouring
technique or dual threshold method, the contents inside the endosteal surface
is selected (step 3 to 4). The cortical shell is step 5 is obtained by binary
subtraction of the region in step 4 from step 2. One method of obtaining the
result in step 6 is obtained by applying the isosurface and isocap functions
for all the processed images in the dataset for cortical and trabecular region
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Fig. 2.4: Segmentation and rendering
separately.
2.14 Morphological analysis
Morphological analysis can be performed by either summing the results from
all the 2D slices or directly from a 3D volumetric model.
Parfitt and colleagues [23] have proposed a standard system of nomen-
clature and their abbreviations to quantify bone histomorphology and this
standard is used by various bone research groups. Morphological analysis in
this thesis was performed using the CT Analyzer program written by Phil
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Salmon. The interested reader may want to experiment with other excellent
programs like BoneJ [32], an ImageJ plugin for bone analysis or The Virtual-
ization Toolkit (vtk) [33], for visualization. Both are updated by the open
source community.
The following sections describes the morphological indices used in this
thesis, with the region of interest in the metaphyseal trabecular region.
2.15 Bone volume fraction, BV/TV
This index refers to the fraction by volume (BV) of mineralized tissue (bone)
within the volume of interest (TV).








Bone volume fraction is dependent on the defined volume of interest. If
the volume of interest has its boundary around the bone endosteal surface,
BV/TV refers to the trabecular bone volume fraction or ratio. It is usually
expressed as a percentage.






This index is one of the most obvious indication of bone loss due to osteo-
porosis caused by estradiol deficiency, which can be induced by menopause
in women or ovariectomy in laboratory rodents, like the OVX rat model for
osteoporosis. Within 2 to 4 weeks after ovariectomy, there is a significant
reduction in BV/TV in 2 to 4 weeks (refer to next chapter 4.6) in the OVX
rat tibia metaphyseal trabecular region compared to a normal control.
2.16 Bone Surface Density, BS/TV
This is an index of the bone tissue surface (BS) within the volume of interest
(TV). Bone loss results in a reduction in BS/TV.
Bone surface, BS, is found by the sum of the total surface area of the
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2.17 Bone surface ratio, BS/BV
The bone surface ratio, also known as specific bone surface is useful in
characterizing and comparing the trabecular surface area to its volume.
Osteoporosis results in the thinning of individual trabecula, increasing the
surface area of the trabecular structure compared to its volume. As a result,
BS/BV of osteoporotic bone is higher than normal bone. In other words, the








This index is more commonly used than bone surface density to show
trabecular bone loss from estrogen deficiency or steroid administration.
2.18 Structure Model Index, SMI
Structure model index provides an indication of the general trabecular ar-
chitecture, whether they are more plate-like or rod-like. The values of SMI
can range from 0 for a perfect plate and 3 for a perfect rod. Following the
degradation of trabeculae by osteoporosis, there is a change from plate-like to
rod-like trabecular architecture. Hence as osteoporosis progress, SMI values
increase from close to 0 towards 3.
SMI is calculated [34] by dilating the segmented bone surface (BS) by
using a 3 × 3 structuring element (E) and measuring the change in bone
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surface caused by the volume dilation. The equation used in the calculation
is given below:
Dilation operation











This indicator is commonly used to provide a general idea of the trabecular
micro-architecture – whether they are mostly built like plates which gives
stronger bone strength or constructed like rods which leads to lower strength.
2.19 Trabecular Thickness, Tb.Th
Trabecular thickness measures the mean thickness of all the trabeculae in
the volume of interest. The reduction in trabecular thickness is one of the
common indicators of osteoporosis due to menopause in women or old age in
men.
In order to calculate this index, the binarized 3D volume is skeletonized,
reducing each trabecula to a line through its medial axis. A method using
sphere fitting [35] is used along the axis to determine the thickness of the
trabecula. At any point, the diameter (D) of the largest sphere that can fit
inside the trabecula will be deemed equivalent to the trabecular thickness at







The distribution of trabecular thickness can be represented in a histogram
to better characterize the degree of trabecular thinning caused by osteoporosis.
A personal observation is that bone loss from osteoporosis does not result
in uniform thinning of all trabeculae at the same rate. In fact, the more
severe the bone loss, the wider the range of trabecular thickness varies (from
very thin to normally thick) compared to the normal control where most
trabeculae are thick.
2.20 Trabecular Separation, Tb.Sp
Bone loss results in a more porous overall trabecular architecture. Trabecular
separation is higher in the osteoporotic bone compared to normal. With the
same method used for measuring trabecular thickness, sphere fitting method
is used to find the trabecular separation. In this case is that the spaces not
occupied by the trabecular region are used instead.
In a similar fashion, osteoporosis results in a higher mean value of trabec-
ular separation, while the normal bone has a lower value. The osteoporotic
bone also has a wider spread of the trabecular separation distances.
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2.21 Trabecular Number, Tb.N
Trabecular number provides the average number of trabeculae by counting the
number of intersections made by a linear path through the region of interest.
As osteoporosis becomes more severe, some trabeculae becomes thinner and
eventually disappear. The number of intersections made by the linear path
becomes lower in osteoporosis bone and is reflected by a lower trabecular
number.
Trabecular number (Tb.N) is related to thickness (Tb.Th) and separation





2.22 Trabecular Porosity, Tb.Po
Trabecular porosity calculates the percentage of all the pores (closed and






Trabecular porosity, Tb.Po, is also sometimes referred to as total porosity,
Po.(tot).
Osteoporosis increases the number and size of the pores in the trabecular
region much faster than the cortical region. Hence, the more severe the
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Table 2.1: Summary of the trabecular bone morphological indices
used, their abbreviations and some brief descriptions
Index (abbreviation) Brief description
Bone Volume Fraction (BV/TV) Percentage of bone volume
Bone Surface Density (BS/TV) Ratio of bone surface to ROI volume
Bone Surface Ratio (BS/BV) Ratio of bone surface to bone volume
Structure Model Index (SMI) Measure of plate or rod likeness
Trabecular Thickness (Tb.Th) Average trabecular thickness
Trabecular Separation (Tb.Sp) Average trabecular separation
Trabecular Number (Tb.N) Average trabecular number
Trabecular Porosity (Tb.Po) Percentage of pores
disease, the higher the trabecular porosity. Trabecular porosity is inversely
related to bone volume fraction discussed Bone volume fraction. Hence, as
osteoporosis advances, bone volume fraction falls and trabecular porosity
rises. A summary of the indices is provided below.
The morphological indices listed here are the ones most commonly used
in literature. For more details, the reader can look at [23]. These indices can
be used in to study bone loss from osteoporosis and evaluate the preventive
effects from bisphosphonates and parathyroid hormone as two classes of drugs
to treat this disease.
Chapter 3
Results
3.1 Visualization of trabecular region
The visualized volume of the metaphyseal region of interest for control
(SHAM), ovariectomized rats with saline vehicle injections (OVX+VEH) and
those given parathyroid hormone (OVX+PTH) or ibandronate (OVX+IBAN)
were shown in Fig. 3.1.
As apparent in Fig. 3.1, there is drastic bone loss in the untreated
(OVX+VEH) group compared to the control (SHAM) group. The therapeutic
effects of the anabolic agent – parathyroid hormone and anti-resorptive agent
– ibandronate in preventing bone loss can be observed from week 6 onwards.
By week 12, both treatment groups are shown to be as effective even though
the mechanisms of drug action is different between them.
Unlike the rabbit osteoporosis model [36], the skeletons of aged rats do not
35
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achieve full skeletal maturity – which is indicated by the fusion of the growth
plate between the epiphysis and metaphysis. In rats, the growth plate usually
does not fuse and is easily observed in the gap between the metaphysis and
epiphysis in micro-CT scans.
3.2 Micro-architectural changes
By analyzing the results from the SHAM1 group, there was denser trabeular
bone at week 12 compared to week 0 due to growth, but this increase was
not significant. Morphological results from Fig. 3.2 to Fig. 3.5 showed no
significant increase for all 7 indices in 12 weeks during the experiment. For
all indices measured, there were no significant variation in morphological
exhibited by the (SHAM) group from the beginning to the end (week 12) of
the experiment. We can then assume that any difference from this control
group is cuased by the effects of estrogen deficiency (OVX+VEH) and the
therapeutic effects of anabolic (OVX+PTH) or anti-resorptive (OVX+IBAN)
treatments.
For the ovariectomized (OVX+VEH) animals, the drop in estrogen levels
from the surgical removal of their ovaries resulted in a significant bone loss as
shown by the drop in BV/TV, Tb.Th and Tb.N by week 6. Similarly, their
trabeculae becomes more rod-like and porous, as indicated by the increase in
SMI, Tb.Po and Tb.Sp compared to the baseline values (SHAM).
1the control group
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With regards to treatment with parathyroid hormone (OVX+PTH), sig-
nificant improvements in BV/TV, BS/BV, SMI and Tb.Po were observed
by 12 weeks. Rats given PTH treatment maintained bone mass as shown in
Tb.Th, Tb.Sp and Tb.N as these indices were not reduced as exhibited in the
untreated (OVX+VEH) group. With ibandronate (OVX+IBAN) treatment,
similar therapeutic effects were observed in the prevention of bone loss with
BV/TV, BS/BV and Tb.Po. Ibandronate prevented bone loss indicted in
Tb.Th, Tb.Sp, Tb.N and SMI, where there were no significant change com-
pared to control (SHAM), even though these group of rats (OVX+IBAN)
had their ovaries removed.
Visualization of drastic bone loss in (OVX+VEH) as early as week 6
is shown in Fig. 3.1. The therapeutic effects of anabolic (OVX+PTH) or
anti-resorptive (OVX+IBAN) treatment are shown alongside for week 6 and
week 12 after ovariectomy surgery.
3.3 Anabolic or Antiresorptive treatment
The rendering of the right tibial metaphyseal region, as shown in Figure 3.1
showed a drastic loss of trabecular bone in the OVX group as early as 6
weeks post surgery. This clearly showed the result ovariectomy-induced bone
loss from the decline in ovarian estradiol. Various bone indices indicated the
loss of trabecular architecture integrity as a result. The indices showed that
trabecular bone loss is already significant on the early onset of osteoporosis,
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Fig. 3.1: Effect of OVX, PTH or IBAN treatment in rat tibiae



















































(b) Bone surface ratio, BS/BV
Fig. 3.2: Graphs of (a) Bone volume fraction and (b) Bone surface
ratio. Significant difference (p < 0.05) from a. SHAM, b. OVX or c.
initial values at 0th week (horizontal dotted line).
which in this case refers to the first 6 weeks after ovariectomy surgery for the
rats.
Bone loss starts to stabilize from 6 week to 12 weeks, indicating that
OVX-induced trabecular bone loss starts to plateau from 6 to 12 weeks after
the initial drastic change in the first 6 weeks.
This trabecular loss can be overcomed by the administration of either an
anabolic agent (e.g. PTH) or an anti-resorptive agent (e.g. ibandronate). Most
micro-CT indices showed either treatment to have improvement compared to
OVX or no deterioration compared to SHAM at most by 12 weeks.
The increase in SMI in the OVX group indicates that the individual
trabecula is becoming more rod-like instead of the plate-like architecture in
the SHAM group. The value of SMI ranges between 0 (for perfect plate-like






















































(b) Trabecular porosity, Tb.Po
Fig. 3.3: Graphs of (a) Structure model index and (b) Trabecular
porosity. Significant difference (p < 0.05) from a. SHAM, b. OVX or c.
initial values at 0th week (horizontal dotted line).
architecture) to 3 (for perfect rod-like architecture) [29]. Apart from SMI,
OVX caused a reduction in BV/TV, Tb.N, Tb.Th and increased Po(tot) and
Tb.Sp.
In this experiment, rats of 8-12 weeks were used at the starting point
(week 0) of the experiment. As bone remodelling could be actively taking
place in rats at the age range, retired breeders [10, 28] could have closer
resemblance to post-menopausal osteoporosis.
In this study, treatments with either an anabolic agent (PTH) or an
anti-resorptive agent (IBAN) have shown significant benefits by preventing
the loss of trabecular bone. We also propose early treatment for osteoporosis
as the most significant changes in the trabecular bone occur during the early
onset of this condition [28, 37, 31].


























































(b) Trabecular separation, Tb.Sp
Fig. 3.4: Graphs of (a) Trabecular thickness and (b) Trabecular
Separation. Significant difference (p < 0.05) from a. SHAM or c.
initial values at 0th week (horizontal dotted line).
3.4 Statistical analysis
A one-way analysis of variance (ANOVA) was performed to determine the
significant difference between different groups for each time point. Bonferroni
corrections were used for multiple comparisons. Differences was considered
significant at p < 0.05.
3.5 Biomarkers of bone turnover
The serum concentration for bone formation marker, procollagen type 1
N-terminal propeptide (P1NP) and bone resorption marker, C-terminal cross-
linked telopeptides of type 1 collagen (CTX) biomarkers were assayed using
ELIZA.


























Fig. 3.5: Graph of Trabecular number. Significant difference (p < 0.05)
from a. SHAM, b. OVX or c. initial values at 0th week (horzontal
dotted line).
At the beginnning of the study at week 0, there were no significant
difference in the levels of P1NP and CTX levels between the different groups.
AT the end of the study at week 12 (after 8 weeks of treatment), both
anabolic (OVX+PTH) and the combined treatment (OVX+PTH+IBAN)
groups showed higher (p < 0.05) levels of bone formation markers compared
to the other groups. Between PTH treatment and the combined treatment
group, combining PTH and IBAN showed 71% higher concentrations of the
bone formation markers, which could indicate that PTH’s anabolic effect is
enhanced when used together with ibandronate.
At 12 weeks, the levels of bone resorption marker for untreated animals
(OVX+VEH) is 113.2% higher (p < 0.05) than the sham-operated control
(SHAM), which is an indicator of the higher bone resorption after ovariec-
tomy that resulted in osteoporotic condition in the OVX group. There is no
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significant difference between untreated (OVX+VEH) and anabolic treated
(OVX+PTH) groups, implying that PTH has no beneficial effect regarding
bone resorption. Both anti-resorptive (OVX+IBAN) and combined treatment
(OVX+PTH+IBAN) groups showed a decrease in CTX levels but the com-
bined treatment is not significantly better than IBAN alone regarding bone
resorption.
3.6 Combining PTH and Ibandronate
3D rendering of the rat femurs allow the visualization and comparison of bone
loss from ovariectomy (OVX+VEH) from control (SHAM). Drastic bone loss
is easily discerned from 2 to 6 weeks after surgery in the OVX group. This
loss was never restored even when the rats (8-12 weeks old) were considered
to have the potential for further bone growth. Effects of treatments with
either PTH, ibandronate or both drugs can be compared at Fig. 3.6.
The visual comparison can be combined with quantitative analysis to
provide comparisons between the efficacy of using either anti-resorptive,
anabolic or the combined treatment to preserve bone loss from ovariectomy-
induced osteoporosis.
Within 6 to 8 weeks after ovariectomy, trabecular morphological indices
differ from SHAM in all parameters (BV/TV, Tb.Th, Tb.Sp, Tb.N, SMI,
Tb.Po). This is in accordance with previous studies [28, 30] which described
the early deterimental effects on trabecular micro-architecture as a result of
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Fig. 3.6: Visualization of single and combined treatments. (voxel size
16.47 µm)
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estrogen deficiency caused by ovariectomy.
(a) Bone volume fraction, BV/TV (b) Structure model index, SMI
Fig. 3.7: Graphs of (a) Bone volume fraction and (b) Structure Model
Index.
(a) Trabecular porosity, Tb.Po (b) Trabecular thickness, Tb.Th
Fig. 3.8: Graphs of (a) Trabecular Porosity and (b) Trabecular Thick-
ness.
Evidence of the anabolic effect by PTH was evident from trabecular
morphology. The PTH treated (OVX+PTH) group showed significant im-
provement in Tb.N and Tb.Sp (+43.2% and -33.4%, p < 0.05) after 4
weeks and (+61.3% and -40.5%, p < 0.05) after 6 weeks of treatment
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(a) Trabecular number, Tb.N (b) Trabecular separation, Tb.Sp
Fig. 3.9: Graphs of (a) Trabecular Number and (b) Trabecular Sepa-
ration.
respectively. At the end of the study, OVX+PTH showed higher Tb.N
(+71.6%, p = 0.024) and lower Tb.Sp (-31.8%, p = 0.006) as compared to
the non-treated group (OVX+VEH). We also observed higher bone volume,
BV/TV(+81.8%, p = 0.008) and lower porosity, Tb.Po (-16.2%, p = 0.008)
at 6 to 8 weeks of PTH treatment.
It was shown that the reduction in bone volume fraction (BV/TV), loss of
trabecular number (Tb.N) and increased trabecular separation (Tb.Sp) can
be prevented using ibandronate treatment in the rat OVX model. We have
observed in this study that ibandronate’s ability to reduce the deterioration
of trabecular micro-architecture occur earlier than PTH. After 2 weeks of
ibandronate treatment, the (OVX+IBAN) group exhibited significant im-
provement from the untreated (OVX+VEH) group in terms of higher bone
volume fraction, BV/TV (+82.9%, p = 0.009), lower structure model index,
SMI (-53.5%, p = 0.009), lower trabecular porosity, Tb.Po (-19.8%, p = 0.009)
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and more trabeculae, Tb.N (+75.2%, p = 0.016). After 4 weeks of ibandronate
treatment, animals in the (OVX+IBAN) group has reduced trabecular sepa-
ration, Tb.Sp (-38.8%, p = 0.015) than the untreated rats (OVX+VEH). At
the end of the study (8 weeks treatment), anti-resorptive treatment in the
(OVX+IBAN) group showed higher bone volume fraction, BV/TV (+78.2%,
p = 0.012) and trabecular number, Tb.N (+76.2%, p = 0.013) and reduced
structure model index, SMI (-21.4%, p = 0.013), trabecular porosity, Tb.Po
(-15.3%, p = 0.012) and trabecular separation, Tb.Sp (50.4%, p < 0.001)
when compared with those without treatment (OVX+VEH).
For the combined treatment group (OVX+PTH+IBAN), there was in-
creased bone volume fraction, BV/TV (+76.2%, p = 0.01) and more numerous
trabecular number, Tb.N (+67.5%, p = 0.021) as well as a significantly lower
porosity, Tb.Po (-18.2%, p = 0.010) and more plate-like trabecula measured




4.1 Ovariectomy-induced bone loss
The most significant reduction occured in bone volume fraction (BV/TV),
trabecular thickness (Tb.Th) and trabecular number (Tb.N) during the first
6-8 weeks after OVX surgery. The amount of bone material decreases, the
trabecular struts became thinner and more rod-like and the bone architecture
became significantly more porous. These results are consistent with previous
studies which reported that irreversible micro-architectural changes happen
within the first 8 to 12 weeks after ovariectomy [28, 10, 31]. Animals in
the SHAM group exhibited higher bone volume fraction (BV/TV) than in
previous studies [28, 10, 31] due to the fact that 12 weeks old mature female
rats were used compared to 6-8 months old retired breeders. There was a more
drastic reduction of 57% in BV/TV whereas previous studies reported 30-40%
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reduction within the same period of 8 weeks after OVX surgery [28, 31].
Bone loss resulting from estradiol deficiency in younger rats is proportionally
more drastic mainly becuase younger rats have denser trabecular bone at
the beginning. Plateaus were observed from 8 weeks onwards for structure
model index (SMI), trabecular thickness (Tb.Th), trabecular number (Tb.N)
for OVX as previously described by Campbell et al [28]. The leveling off
of micro-architectural changes was observed even in the treatment groups.
Thus, drastic structural changes following estrogen deficiency in menopause
and the leveling off in microarchitectural indices illustrate the importance of
early treatment in osteoporosis in order to prevent further deterioration in
bone micro-architecture.
4.2 Beneficial effects of ibandronate
Ibandronate has a dual role of inhibiting bone resorption and also forma-
tion, thereby reducing bone turnover rate [44, 57], protecting the trabecular
strucutre from the deleterious effects of bone resorption. After 2-4 weeks of
administration, the anti-resorptive effect of ibandronate resulted in higher
bone volume fraction (BV/TV), trabecular number (Tb.N) and reduced
structure model index (SMI), trabecular separation (Tb.Sp) and trabecular
porosity (Tb.Po) compared to the placebo group, (OVX+VEH). Studies by
Smith, et al [58] showed a similar effect using ibandronate in preventing bone
loss and maintaining bone strength in ovariectomized cynomolgus monkeys.
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Even though the positive effects of ibandronate could be observed as early as
2-4 weeks after administration, its effects will reach a plateau as indicated in
the micro-CT indices.
4.3 Beneficial effects of PTH
The truncated Parathyroid Hormone, PTH(1-34), stimulates both bone forma-
tion and also bone resorption [59], promoting bone remodelling rate. The net
outcome can produce a catabolic or anabolic effect on trabecular bone depend-
ing on dosage and frequency of administration [59, 60]. The comparatively
higher PTH to ibandronate ratio and intermittent PTH administraton used in
out study had shown a net anabolic effect on BV/TV, Tb.Sp and Tb.Po from
the 10th week after OVX surgery. We have observed that the beneficial effects
of PTH on bone micro-architectural indices were only significant after 6 weeks
of treatment as compared to ibandronate at 2 weeks. This fact suggests that
ibandronate is more effective at preventing the deterioration of trabecular
bone than PTH earlier.
4.4 Beneficial effects of combining PTH with
ibandronate
Previous studies using alendronate have shown that it may negatively reduce
PTH’s anabolic effects on bone tissues [15, 46, 47]. However, in our study
4.5. SERUM LEVELS OF BONE BIOMARKERS 51
using the combined PTH and ibandronate treatment, significant increased
bone volume fraction (BV/TV) and trabecular number (Tb.N) while achieving
lower Structure Model Index (SMI) and trabecular porosity (Tb.Po) from the
second week after treatment initiation as compared to individual treaments.
This suggests that ibandronate does not reduce PTH’s anabolic effects. Thus,
we believe that the combined therapy results in a positive effect on bone
quality by preserving the bone’s trabecular micro-architecture.
4.5 Serum levels of bone biomarkers
From the biomarker results, anabolic treatment (OVX+PTH) had signifi-
cantly higher (p < 0.0005) levels of bone formation marker (P1NP) than
the untreated (OVX+VEH) group. On the other hand, the bone resorption
marker (CTX) levels with anabolic (OVX+PTH) treatment is not significantly
different from the untreated (OVX+VEH) group. This shows that the current
PTH treatment resulted in higher bone formation, but had no influence on
bone resorption.
Anti-resorptive treatment (OVX+IBAN) had significantly lower (p =
0.015) levels of bone resorption markers compared to the untreated (OVX+VEH)
group but the formation markers of (OVX+IBAN) did not show any signif-
icant difference from (OVX+VEH) group. This showed that ibandronate
treatment resulted in reduced levels of bone resorption, but had no influence
on bone formation. Overall, the single anabolic treatment (OVX+PTH)
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group showed only increased bone formation while single anti-resorptive treat-
ment (OVX+IBAN) group showed only decreased bone resorption, which is
consistent with previous reports [61, 62].
Looking at the combined treatment (OVX+PTH+IBAN), levels of bone
formation marker (P1NP) was higher (p < 0.001) and the levels of bone
resorption marker (CTX) was lower (p = 0.04). This shows that the concurrent
treatment has additional advantages where bone formation is heightened while
bone resorption is depressed.
Bone resorption markers in the combined treatment group (OVX+PTH+IBAN)
did not differ significantly from anti-resorptive treated group (OVX+IBAN),
whereas the formation markers were significantly higher (p < 0.001) than the
anabolic treated (OVX+PTH) group. This shows that PTH has no additional
improvement on ibandronate’s anti-resorptive actions whereas the combined
treatment improved the anabolic effect of PTH.
4.6 Drug ratio
While many of the previous studies show a counter additive effect on concur-
rent administration of both anabolic and anti-resorptive drugs [15, 46, 47],
a partial additive effect was observed in this study. To the best of our
knowledge, this is the first study to assess the concurrent administration of a
3rd-generation bisphosphonate, ibandronate, and PTH in an OVX rat model.
Previous studies have analysed the additive effect of the 2nd-generation bis-
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phosphonates, alendronate, alongside PTH [15, 16, 45, 46, 47, 48, 49]. While
other bisphosphonates require frequent administration to maintain their thera-
peutic effect, Bauss, et al [51] have shown that that the effects of ibandronate
is accumulative and independent on the frequency of drug administration.
We have adopted a relatively high dosage ratio of PTH to ibandronate by
weekly administration with reference to current therapies for the OVX mice
model [48, 63]. Our aim is to administer weekly low dosages of both PTH
and ibandronate (higher PTH to ibandronate ratio) to prevent undesirable
effects of using high dosages as observed in rats [64, 65]. Higher dosages and
extended regimes of PTH (1-34) have been reported in other studies on rats
[64, 65]. Sato, et al reported that a daily dosage of 8µg/kg of PTH (1-34)
for 1 year in OVX rats can lead to 11% increase in cortical bone brittleness
[65]. The undesirable side effects of PTH (1-34) include hypercalcemia in
clinical studies [65], headaches, nausea and back pain. As a result, we have
reduced the PTH (1-34) administration frequency from daily to weekly to
circumvent the undesirable side effects. We have adopted the dosage and
frequency of PTH administration according to studies done by Gittens et al
[50]. By comparing results from their studies and our results, the optimal
dosage for PTH (1-34) could be between 20-40 µg/kg for 4 weeks in order
for bone anabolic effect to accumulate bone mass in the OVX rat model.
It is also reported that weekly administration of PTH increases in bone
mass as effectively as daily administration at the same accumulated dose
[66, 67]. These data reinforces the importance of conducting pre-clinical trials
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to evaluate the optimized dosage of PTH in bone regeneration [68].
We have conducted a pilot study with relatively low dosage with weekly
administration of PTH (1-34) and ibandronate. A higher ratio of anabolic
to anti-resorptive agent is less likely to inhibit the bone formation function
by PTH in this study. We believe this additive effect between PTH and
ibandronate can be attributed to the optimal dosage and ratio so that the
effect of PTH can be increased when a potent anti-resorptive agent like
ibandronate is used either concurrently or alternatively.
In previous rodent studies, the effect of concurrent treatment using PTH
and bisphosphonate was additive at drug ratios of 1:0.3 [48] and 1:0.2 [68]. On
the other hand, antagonistic effect from alendronate was shown at dose ratio
of 1:100 [15] and 1:250 [47]. In this study, we have utilized a PTH:ibandronate
ratio of 1:0.7 according to previous studies [44, 50, 51]. A threshold ratio
can be postulated for future studies. If the dosage of bisphosphonate goes
beyond this threshold, no additive effect would be observed. Below this
threshold, an increase in PTH dosage may lead to an increase in additive
effect correspondingly [68]. Further histomorphometric studies could be
conducted to better illustrate the mechanism of these effects. Apart from dose
and ratio, other factors such as the nature of drug administration (daily, cyclic,
alternative) that can also affect the results of this combination therapy.
Chapter 5
Conclusion
5.1 Importance of early intervention
These results are in accord with previous studies which claim that the degrees
of osteoporosis can best be determined at the trabecular-rich metaphyseal
femur or tibia of the rat [71, 72]. Our study [69] shows that micro-achitectural
changes of trabecular bone occurs in the early stage of osteoporosis, which
is not adequately represented using the total BMD of the bone alone. Early
intervention using treatments using anabolic or anti-resorptive have shown
to be effective in reversing this trabecular bone loss in order to combat
osteoporosis.
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5.2 Additive effect
Our study investigates the therapeutic effects of anabolic and anti-resorptive
therapies [69] and their additive effect [70] to restore bone loss brought about
by ovariectomy-induced estrogen deficiency in the rat osteoporosis model.
The additive effect may be attributed to the proper drug dosage and ratio
combined with the appropriate course of treatment. Futher exploration of this
findings will allow us to fine-tune this ratio and to maximize the beneficial
effects from the concurrent administration of the two drugs in the treatment
of osteoporosis.
5.3 Future work
The geometrical data from micro-CT datasets can be further used for input
as micro-finite element analysis to display the region that is under high levels
of stress or strain.
Fig. 5.1 illustrates an example during when the weight of the rat is applied
onto a micro-finite element model built from the cortical geometry of the
micro-CT datasets. The distributed stress for 1 to 3 second is displayed.
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Fig. 5.1: Stress distribution in tibia (cortical region) from micro-CT
data.
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Morphological and Mechanical Changes in Ovariectomized Rat 
Tibia with Treatments of Ibandronate and Parathyroid Hormone
Xiao Yang*, Yong Hoow Chan*, Padmalosini Muthukumaran, Taeyong Lee
Division of Bioengineering, Faculty of Engineering, National University of Singapore, Singapore
Osteoporosis is a debilitating disease affecting the elderly population, associated with compromised 
stability and reduced mobility of the bone. Osteoporosis is diagnosed as a condition when the measured 
bone mineral density (BMD) falls below 2.5 standard deviations of peak mass. However, BMD alone might 
not be enough to define the osteoporotic condition because it does not accounts on the 
micro-architectural changes in the bone trabeculae. Thus, this study aimed at studying the micro- 
architecural changes in trabeculae rich bone metaphysis of ovariectomized rat models in comparison 
with the conventional BMD measurements and the mechanical parameters. In this study, proximal tibiae 
of twenty-five female rats from four different groups (SHAM, OVX, IBAN and PTH) were evaluated using 
micro-CT, pQCT and three point bending tests. The micro-CT analysis showed that the deterioration of 
trabecular bone was significant during the first 6 weeks after OVX surgery. During the early stage of 
osteoporosis, the trabecular density decreased more rapidly than the cortical density. Morphological 
analysis showed that early administration of both ibandronate and parathyroid hormone has a beneficial 
effect on restoring the trabecular structures. Bone mechanical properties of treatment groups did not 
show significant difference, but followed the overall trend as morphological indices. The results suggest 
that early administration of either ibandronate or PTH is effective in restoring the trabecular bone loss 
caused by osteoporosis. However, larger-scale studies should be conducted to better understand the 
effect of both anti-resorptive and anabolic treatments in terms of morphological and mechanical 
properties.
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  Osteoporosis is becoming a major health concern, 
especially in the elderly population. World Health 
Organization (WHO) defines osteoporosis as a condi-
tion where the bone mineral density (BMD) falls below 
2.5 standard deviations of peak mass as measured by 
DXA, further leading to fragility fractures. Osteoporosis 
is also associated with compromised stability and 
reduced mobility of the patients.1
  Two distinct classes of drugs, the anabolic and anti- 
resorptive drugs, are commercially available on the 
market and are proved to be effective in treating osteo-
porosis. Human Parathyroid Hormone (hPTH (1-34)) is 
an anabolic drug and it is shown to have an effect on 
bone structural properties in animal models1 as well as 
human beings2,3 by increasing bone formation rate. 
Bisphosphonates (such as ibandronate and alendronate) 
are a class of anti-resorptive drug and are shown to 
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suppress bone resorption. Ibandronate is a third genera-
tion nitrogen-containing bisphosphonate and is shown to 
successfully suppress bone resorption.4,5
  Some studies show that there is no synergetic effect of 
hPTH (1-34) and alendronate on post-menopausal women, 
in terms of changes in BMD and the serum concentration 
of biomarkers of bone metabolism.3 For the prediction of 
fracture, however, BMD data does not provide sufficient 
evaluation on trabecular architecture6 and the stiffness of 
bone,7 which are critical factors in evaluating bone 
strength. Higher BMD does not necessarily mean lower 
possibility of fracture.8-13 But, the crucial point in 
osteoporosis is to best predict the fracture risk. Previous 
studies have shown that fractures predominantly occurred 
at the metaphysis of long bones in rats7. Therefore, in 
ovariectomized (OVX) rat models, the degree of 
osteoporosis could be determined at the trabaculae-rich 
metaphysis of tibia by bending tests14,15 and 3D micro- 
architectural analysis of trabecular bone.16,17
  Ibandronate has been proven to be effective in 
inhibiting bone resorption at lower doses compared to 
other bisphosphonates in animal models.18-20 But, little 
was known about the effect of hPTH (1-34), iban-
dronate on structural and morphological changes in the 
tibia of the ovariectomized rat models. Therefore, a 
pilot study was conducted to study the effect of the 
anabolic and anti-resorptive therapies on the bone 
strength and micro-architectural changes at the tibia 
metaphysis. This paper addresses on the changes in 
mechanical and morphological indices in ovariectomi-




  Twenty-five female Sprague-Dawley (SD) rats of age 
6～8 weeks were housed at 25 oC with 12:12-hour 
light-dark cycle at Laboratory Animal Centre, National 
University of Singapore. They were given standard 
rodent diet (Harland, Model T.2018S) and water ad 
libitum. The animals were subjected to OVX or sham 
surgery after acclimatizing for one week at the 
Laboratory Animal Centre. All animal experiments were 
conducted in accordance with the approved protocol 
from the Institutional Animal Care and Use Committee 
(IACUC) at the National University of Singapore.
  The rats were divided into the following four groups 
with weekly subcutaneous administration of (n=6 for 
each group, except sham, n=4): (1) Vehicle-treated sham- 
operated group (SHAM group); (2) Vehicle- treated OVX 
group (OVX group); (3) hPTH (1-4)-treated OVX group 
(OVX+PTH group) and (4) Ibandronate- treated OVX 
group (OVX+IBAN group). The remaining three rats 
were used for evaluating baseline data.
  Human hPTH (hPTH 1-34, Sigma-Aldrich, Singapore) 
and ibandronic acid (Roche Diagnostics GmbH, 
Mannheim, Germany) were dissolved in 0.9% saline. 
hPTH (1-34) (10 μg/kg body weight), ibandronate (7 
μg/kg body weight ) or its vehicle (0.9% saline) was 
administered subcutaneously every week, starting from 
fourth week post-surgery. Three rats were euthanized on 
0th day to obtain the initial time point data. Sub-
sequently, two rats from the sham group were 
euthanized after 6 and 12 weeks. Three animals each 
from the remaining groups were euthanized after 6 and 
12 weeks. The right tibia of the rats were harvested, 
wrapped in PBS soaked gauze and stored at -20 oC. 
Before the experiment, the bone specimens were thawed 
to room temperature using PBS.
 2. In-Vitro Micro Computed Tomography 
(µCT)
  Micro-CT scanning was done in vitro in the 
transverse axial direction using SMX-100CT (Shimadzu, 
Kyoto Japan). A volume of interest 3.63 mm thick (220 
micro-tomographic slices) of the right proximal tibia 
was acquired, 1mm distal to and extending from the 
growth plate with an isotropic voxel size of 16.5 μm 
(46 kV, 56 μA, 1200 views, cone-beam reconstruction) 
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Fig. 1. Proximal region of a rat tibia analyzed by μCT. 
Fig. 2. pQCT picture with in vitro tibia sample.
(Fig. 1). A semi-automated contouring method was used 
to isolate the trabecular region in the images from 
micro-CT. The grayscale datasets were globally thres-
hold (28% of the maximal grayscale value) to form 
binary images for the analysis of trabecular architecture. 
Direct 3D measurements were used to assess bone 
volume ratio (BV/TV), bone surface ratio (BS/BV), 
structure model index (SMI), trabecular thickness 
(Tb.Th), trabecular number (Tb.N), trabecular separation 
(Tb.Sp) and total porosity (Po (tot)) in the trabecular 
bone (CT Analyzer, SkyScan, Belgium). Tibias repre-
senting each time point (0, 6 and 12 weeks after 
surgery and treatment) were scanned and analysed.
3. Peripheral Quantitative Computed Tomo-
graphy (pQCT)
  After thawing, the right tibia samples were subjected 
to ex-vivo pQCT scanning. The pQCT scanning was 
done with a voxel size of 0.1mm and slice thickness of 
0.5 mm using StraTEC’s XCT (Research SA+, StraTEC 
Medizintechnik, GmbH, Pforzheim, Germany). The tibia 
sample is placed inside a 15 ml falcon filled with 0.9% 
saline. The falcon is then placed in the equipment as 
shown in Fig. 2. To enable exact positioning of the 
bone specimens every time, a scout view was performed 
prior to the actual CT-scan. The threshold (separating 
soft tissue from bone) was defined as 280 mg/cm3 while 
the inner threshold (separating sub-cortical from 
trabecular bone) was set at 550 mg/cm3. As it was 
hypothesized that there would be increased osteoporotic 
activity at trabeculae-rich region, significant reductions 
in bone density was expected to occur at the 
metaphyseal region of tibia due to the larger bone 
surface area. Hence, proximal metaphyseal region of the 
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Fig. 3. Custom-made 3-point bending jig for rat tibia.
Fig. 4. 3-dimensional images of the tibial metaphysis of 
4 groups (SHAM, OVX, OVX+PTH and OVX+
IBAN) at the time of operation (0 week) and follow- 
up measurements 6, 12 weeks later. 
tibia was selected to obtain representative total density 
and trabecular bone density values.
4. Mechanical Testing
  A newly developed testing protocol was adopted for 
the three point bending test of metaphyseal tibia.7 A 
micro-tester (model 5848, Instron, Norwood, MA USA) 
with a measuring range from 2 to 1000 N at a 
precision of 0.2% of the load was used. The speed of 
the feed motion was 5mm/s and the automatic switch 
off-pressure was set at 300 N. In order to avoid 
bursting of the tibia, the trial was automatically ended 
by a drop in strength of >20 N or a liner displacement 
of >2 mm. The maximum load (Fmax), yield load (Fy) 
and stiffness (S) were recorded using “Merlin” 
software. Yield load (Fy) was determined by 0.2% 
offset method. The tibia were thawed and continuously 
moistened with isotonic saline solution during the test. 
Each tibia was placed with the three-point contact on 
the aluminum base (Fig. 3). The base was fixed in the 
system such that the distance between the end of the 
proximal tibia (without the epiphysis) and the center of 
the roller stamp is exactly 3 mm. 
5. Statistical Analysis
  SPSS 16.0 software was used for statistical analysis. 
Mean and standard deviation of all the variables were 
reported. One-way ANOVA was performed by time to 
determine significant difference between different groups 
for each time point. Similarly, one-way ANOVA tests were 
also performed by groups to find out significant differences 
of each group over the time period. Bonferroni corrections 
were used for all the comparisons. Results were considered 
to be statistically significant when p value is less than 0.05.
RESULTS
1. In-Vitro Micro Computed Tomography 
(µCT)
  The cross sectional view of rat tibial metaphysis, as 
obtained from micro-CT, is shown in Fig. 4. The 
morphological indices obtained from micro-CT 
scanning are given in Table 1. The changes in the bone 
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Parameter Group



















 0.79±0.39  0.70±0.28
OVX  2.19±0.43§  2.37±0.25†§
OVX+PTH  1.40±0.21  1.40±0.18‡











 0.16±0.006  0.15±0.009
OVX  0.12±0.001†§  0.12±0.005†§
OVX+PTH  0.14±0.002†§  0.14±0.007




 0.22±0.03  0.20±0.003
OVX  0.74±0.15†§  0.69±0.11†
OVX+PTH  0.45±0.01  0.45±0.14




 2.79±0.37  3.13±0.32
OVX  1.12±0.22†§  1.05±0.18†§
OVX+PTH  2.05±0.16  2.21±0.26
OVX+IBAN 63.08±0.96 70.69±8.27
†P<0.05, as compared to SHAM, ‡P<0.05, for treatment groups as compared to  OVX, §P<0.05, as compared to 
baseline value
Table 1. Micro-CT indices of different groups at 0, 6 and 12 weeks post-surgery
volume ratio (BV/TV), bone surface ratio (BS/BV), 
structure model index (SMI), total porosity (Po (tot)), 
trabecular thickness (Tb.Th), trabecular separation 
(Tb.Sp) and trabecular number (Tb.N) of various 
groups at different time are shown in Fig. 5A to 5G 
respectively.
  There was no longitudinal variation in the mor-
phological indices in the SHAM group. In the OVX 
group at 6 week post-ovariectomy, BV/TV, Tb.Th and 
Tb.N decreased significantly from 0th week and SMI, 
Po (tot) and Tb.Sp increased significantly from 0th 
week. However, the values of the micro-CT indices at 
12 weeks were similar to those of 6 week. The effect 
of ibandronate and PTH administration was evident, as 
the changes in these morphological indices due to 
ovariectomy was overcome in the treatment groups, and 
a significant difference was observed at each point in 
both the treatment groups as compared to the OVX 
group.
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†P<0.05, as compared to SHAM, ‡P<0.05, for treatment groups as compared to  OVX, §P<0.05, as compared to baseline value
Fig. 5. Changes in mCT indices of different groups at 0, 6 and 12 weeks.
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Fig. 6. pQCT image of different groups at 12 week 
post-surgery
Parameter Group
















†P<0.05, as compared to SHAM, ‡P<0.05, for treatment groups as compared to  OVX, §P<0.05, as compared to 
baseline value, ¶P<0.05, as compared between 6 and 12 weeks
Table 2. pQCT indices of different groups at 0, 6 and 12 weeks post-surgery
†P<0.05, as compared to SHAM, ‡P<0.05, for treatment groups as 
compared to OVX, §P<0.05, as compared to baseline value, ¶P<0.05, 
as compared between 6 and 12 weeks
Fig. 7. Changes in bone mineral density (A) and trabecular 
density (B) of 4 groups (SHAM, OVX, OVX+PTH 
and OVX+IBAN) at 0, 6 and 12 weeks.
2. Peripheral Quantitative Computed Tomo-
graphy (pQCT)
  The cross sectional view of the bone at tibia 
metaphysis, as obtained from pQCT, is shown in Fig. 
6. Table 2 lists the bone mineral density and trabecular 
density of the different groups at 0, 6 and 12 weeks 
post surgery. Fig. 7A and 7B represents the changes in 
the bone mineral density (BMD) and trabecular density 
(Trab D) with respect to the initial time point data.
  The BMD of the SHAM group rat progressively 
increased with respect to time. The BMD of the SHAM 
group increased by 22.8% in 12 weeks (P=0.015). In 
SHAM group, the Trab D also increased by 22% in 12 
weeks (P=0.041). In OVX group, the BMD did not 
vary during the course of the experiment. But, Trab.D 
of OVX group decreased by 42.7% in 6 weeks (P< 
0.001) and 48.4% in 12 weeks (P<0.001). One way 
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Fig. 8. Changes in bone mineral density (A) and trabecular density (B) of 4 groups (SHAM, OVX, OVX+PTH and OVX+IBAN) 
at 0, 6 and 12 weeks
Parameter Group





 74.57±6.26  86.65±7.45
OVX  57.53±18.35  48.89±12.05
OVX+PTH  62.66±7.10  74.03±27.21




 46.73±7.80  74.64±20.01
OVX  48.14±10.47  36.39±14.61
OVX+PTH  38.80±6.73  43.18±10.83








Table 3. Mechanical property parameters of different groups at 0, 6 and 12 weeks post-surgery
ANOVA of the BMD of different groups at 12 weeks 
revealed a significant difference between OVX and 
SHAM group. The OVX+IBAN group showed an 
increased BMD compared to the OVX group. But, 
OVX+PTH group did not show any significant 
variation in BMD from the OVX group. However, both 
the OVX+IBAN and OVX+PTH group showed a 
significant increase in the Trab.D as compared to the 
OVX group in the 12 week analysis. But, this increase 
in Trab.D was not sufficient, as shown by a significant 
difference in the Trab.D in the treatment groups as 
compared with the SHAM group. 
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3. Mechanical Testing
  The maximum load (Fmax), yield load (Fy) and 
stiffness (S) of different groups at 0, 6 and 12 week 
are shown in Table 3. The changes in Fmax, Fy and S 
with respect to the 0 week data are shown in Fig. 8A, 
8B and 8C respectively. Although not statistically 
significant, the Fmax, Fy and S of the OVX group was 
lower than the SHAM group. The treatments groups 
showed intermediate values between OVX and SHAM 
group.
DISCUSSION
  The cross sectional view of the bone at the tibial 
metaphysis, as visualized from both micro-CT and 
pQCT analysis (Fig. 4 and Fig. 6 respectively) showed 
an apparent loss of trabecular bone in the OVX group 
as early as 6 weeks post-surgery. This shows that 
ovariectomy has adverse effect on the trabecular 
architecture at the tibia metaphysis. The trabecular loss 
is overcome by the administration of ibandronate and 
hPTH. Six out of seven micro-CT indices (BV/TV, 
Tb.Th, Tb.Sp, Tb.N, SMI and Po (tot)) showed signi-
ficant changes from the base line 6 weeks after surgery. 
BS/BV showed significant difference 12 weeks after 
surgery. Trab D also showed a highly significant 
decrease in the initial 6 weeks. This shows that 
trabecular bone loss is highly significant on the early 
onset of osteoporosis, in this case during the first 6 
weeks after OVX surgery. However, there is no 
significant difference in those structural indices from 6 
week to 12 week, indicating that the OVX induced 
changes in trabecular bone reaches a plateau after 6 
weeks.
  Significant decrease in the SMI occurs during first 6 
weeks in the OVX group, indicating that trabecular 
architecture is becoming more rod-like compared to a 
more plate-like architecture in SHAM group. The value 
of SMI falls between 0 (perfect plate-like trabecular 
architecture) and 3 (perfect-rod like trabecular architec-
ture).21 Other changes in trabecular bone during the 
first 6 weeks include decreased BV/TV, Tb.N, Tb.Th 
and increased Po (tot) and Tb.Sp. 
  On the other hand, the trabecular density kept on 
increasing in the SHAM group during the course of 
study without any apparent difference in the micro-CT 
indices. This indicates that the rats (2 months old at the 
start of the study) continue to grow and bone remo-
delling is actively taking place in contrast to the retired 
breeders used in other studies.16,22
  The total BMD showed a significant difference only 
after 12 weeks whereas the Trab. D decreased rapidly 
in the initial period indicating that osteoporosis affects 
the trabecular bone more dramatically than the cortical 
bone. This shows the importance of analyzing a 
trabecular rich region such as metaphyseal tibia for 
monitoring osteoporosis. In this study, treatments with 
either PTH (anabolic) or ibandronate (anti-resorptive) 
are shown to have significant beneficial effect on 
restoring the trabecular architecture. We also emphasize 
the importance of early treatment for osteoporosis as 
most of the significant changes in the trabecular bone 
occur during the early onset of the condition.22-24
  Although there is no statistically significant diffe-
rence in the Fmax, Fy and S, the overall trend of Fmax 
and Fy shows a similar pattern as Trab D. The results 
support the previous studies which claim that the 
degree of osteoporosis can be best determined at the 
trabeculae rich metaphyseal femur or tibia of the rat 
indicating that trabecular density is a key parameter.25,26 
Between ibandronate and PTH treated groups, Fy of 
two groups differs more than Fmax although no signifi-
cant difference was found. The PTH treated group has 
relatively low Fy than ibandronate group while both has 
similar Fmax. It can be assumed that there will be 
similar fracture protection in ibandronate and PTH 
treated group at a unique higher force (e.g., a fall), 
whereas lower force (e.g., obesity, a hit etc.) will lead 
to earlier micro-fracturing with OVX+PTH group than 
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with OVX+IBAN group. In the respect of preventing 
creep fracture developed by micro-fractures (e.g., 
multiple minor traumas) at lower force, ibandronate 
confers better effect than PTH.
  Thus our study shows that micro-architectural 
changes of trabecular bone occurs during the early 
stage of osteoporosis, which is not reflected in the total 
BMD. Earlier administration of ibandronate and hPTH 
is shown to be effective in reversing the trabecular 
bone loss. One limitation of the study is that the 
sample size is small. Large-scale studies will be 
conducted to prove the effect of early administration of 
the drug and to study the synergistic effect of the 
concurrent administration of both the drugs.
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Osteoporosis remains a challenging problem. Understanding the regulation on osteoclast and osteoblast by
drugs has been of great interest. Both anabolic and anti-resorptive drugs yield positive results in the
treatment of osteoporosis. However, whether the concurrent administration of parathyroid hormone (1–
34) and ibandronate may offer an advantage over monotherapy is still unknown. This study, therefore,
attempts to compare the efﬁcacy of two therapeutical approaches and to investigate the beneﬁcial effects
in concurrent therapy in a rat model using three-point bending, pQCT and μCT analysis. A total of 60
female Sprague–Dawley rats of age 10 to 12 weeks were divided into 5 groups (SHAM, OVX+VEH, OVX+
PTH, OVX+IBAN, OVX+PTH+IBAN) and subjected to ovariectomy or sham surgery accordingly. Low-
dose parathyroid hormone (PTH) and/or ibandronate or its vehicle were administered subcutaneously to
the respective groups starting from 4th week post-surgery at weekly intervals. Three rats from each group
were euthanized every 2 weeks and their tibiae were harvested. The tibiae were subjected to metaphyseal
three-point bending, pQCT and μCT analysis. Serum biomarkers for both bone formation (P1NP) and
resorption (CTX) were studied. A total of 11 indices showed a signiﬁcant difference between SHAM and
OVX+VEH groups, suggesting the successful establishment of osteoporosis in the rat model. Compared to
the previous studies which showed impedance from bisphosphonates in combination therapy with PTH,
our study revealed that ibandronate does not block the anabolic effects of PTH in ovariectomized rat tibiae.
Maximum load, strength–strain indices and serum bone formation markers of OVX+PTH+IBAN group
are signiﬁcantly higher than both monotherapy groups. With the proper ratio of anabolic and anti-
resorptive drugs, the effect could be more pronounced.
© 2011 Elsevier Inc. All rights reserved.
Introduction
Osteoporosis is a progressive debilitating disease that often leads
to pain, nerve compression and even fracture caused by the reduction
in bone strength and compromised stability [1–3]. After years of
clinical studies in the treatment of osteoporosis, two distinct classes of
drugs, namely the anabolic and anti-resorptive agents, proved to be
effective and are now available on the market. Intermittent admin-
istration of parathyroid hormone (PTH) has been shown to have an
anabolic effect on bone structural properties in animal models [4] and
humans [5,6]. It increases bone strength primarily by stimulating bone
formation. Alternatively, third generation nitrogen-containing
bisphosphonates such as ibandronate and zoledronate have been
successfully used to prevent fracture by suppressing bone resorption
[7–10]. Ibandronate has been proven effective in inhibiting bone
resorption at considerably lower doses than other bisphosphonates in
both rats [11] and ovariohysterectomized dogs [12,13]. Following
long-term treatment with ibandronate, bone mass, strength and
architecture were maintained, or even improved [14].
Whether the concurrent use of bisphosphonate and PTH would
produce an additive effect by reducing fracture risks is still
controversial [5,15–19]. Black et al. have reported that a combined
therapy of PTH (1–84) and alendronate has no synergistic effect on
postmenopausal women, in terms of changes in bone mineral density
(BMD) and mean percent changes in biomarkers of bone metabolism
[5]. However, BMD measurement does not provide sufﬁcient
evaluation of the trabecular architecture [20], actual stiffness or the
ability to withstand an applied force on bones [21]. Furthermore, it is
becoming generally accepted that high BMD does not always relate to
low fracture risk [22–25]. Additionally, a recent ovariectomized
rodent study discovered that the effect of combined administration
of alendronate and PTH (1–34) on bone strength is synergistic in the
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lumbar vertebra and additive in the femur [18]. In order to ensure the
efﬁcacious use of pharmaceutical materials, it is essential to
investigate the interaction and the net effect of parathyroid hormone
with newly approved bisphosphonates. From another aspect, it
provides a basic understanding on drug combinations for future
consequential or alternative administration.
Therefore, we conducted a study to see whether there is a
beneﬁcial effect of the anabolic and anti-resorptive therapies in the
ovariectomized rats. We hypothesized that the combination
therapy with PTH (1–34) and ibandronate would offer an
advantage over monotherapy, in terms of bone mineral density
combined with micro-architectural changes [26] and eventually
bone strength. The weekly low dosages of both PTH and
Ibandronate adopted in this study were selected respectively
from individual dosing tests and also served to circumvent the
negative side effects present in higher doses[14,27,28]. To test this
hypothesis, we compared the micro-architectural and mechanical
changes of OVX rat tibiae in the following three treatment groups:
PTH (1–34) alone, ibandronate alone and combined administration
of PTH (1–34) and ibandronate.
Materials and methods
Overall study design
Sixty female Sprague–Dawley rats (Laboratory Animal Centre,
National University of Singapore) aged 10 to 12 weeks were housed at
25 °C under a 12:12-hour light–dark cycle. They were fed a standard
rodent diet (Harland, Model T.2018S) and water ad libitum. The
animals were subjected to OVX or sham surgery 1 week after
acclimatization at the animal holding unit. All animal experiments
were conducted in accordance with the approved protocol from the
Institutional Animal Care and Use Committee (IACUC) at the National
University of Singapore.
The rats were divided into 5 groups (SHAM, OVX+VEH, OVX+
PTH, OVX+IBAN and OVX+PTH+IBAN) with weekly subcutane-
ous administration of either saline vehicle, PTH, ibandronate or both
drugs. The study was carried at 6 predetermined time points for
SHAM (0, 4, 6, 8, 10 and 12 weeks) and OVX (2, 4, 6, 8, 10,
12 weeks) and 4 time points for treatment (6, 8, 10 and 12 weeks).
There were 12 animals in each group, generating 24 samples (both
tibiae) per group, with n=6 samples per time point for each
treatment (OVX+PTH, OVX+IBAN and OVX+PTH+IBAN) and
n=4 samples per time point each for OVX and sham control groups
(OVX+VEH and SHAM). The animals did not exhibit signs of
distress or illness from the surgery or drug treatments during the
course of the study and none were excluded from the study.
Human parathyroid hormone (PTH 1–34, Sigma-Aldrich,
Singapore) and ibandronate (Roche Diagnostics GmbH, Mannheim,
Germany) were diluted with 0.9% saline. From 4th week post-
surgery, PTH (1–34) (10 μg/kg body weight) [27], ibandronate
(7 μg/kg body weight) [28] or its vehicle (0.9% saline) was
administered subcutaneously once a week for 8 weeks to the
respective groups.
Every 2 weeks, two animals from SHAM and OVX and three from
each treatment groups were euthanized by carbon dioxide asphyx-
iation. Both right and left tibial bones were harvested, wrapped in
0.9% saline soaked guaze and stored at −20 °C until used for the
experiments. From the study of osteoporotic bone fracture using rat
models, the majority of fractures was observed at the metaphysis of
long bones [21] where a rapid deterioration of trabecular bone occurs
[29]. Thus, the trabecula-abundant metaphyseal tibia is a suitable
region to determine the degree of osteoporosis by bending tests
[21,30] and 3Dmicro-architectural analysis of trabecular bone [29,31]
in ovariectomized (OVX) rat models.
Micro-computed tomography (μCT)
The metaphysis region (Fig. 1A) of the right proximal tibia was
scanned ex vivo in an upright position with a source to object distance
(SOD) of 41 mm and a source to image distance (SID) of 339 mm [32]
using a SMX-100CT μCT scanner (Shimadzu, Kyoto, Japan). A 3.29-
mm-thick volume of interest (VOI, 200 slices) was obtained starting
from 1 mm distal to the proximal growth plate [26]. The resultant
grayscale images obtained had an isotropic voxel size of 16.47 μm
from cone-beam reconstruction (46 kV, 49 μA, scaling coefﬁcient of 50
and averaged 3 times).
A semi-automated contouring method was employed to select
trabecular from cortical bone. The grayscale images were segmented
using a global threshold of 15.0% of the maximal grayscale value [33]
using the CT Analyzer software (Skyscan, Phil Salmon). Three-
dimensional analyses [32] was used to assess bone volume fraction
(BV/TV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp),
trabecular number (Tb.N), structural model index (SMI) and
trabecular porosity (Tb.Po) for the same VOI.
Peripheral quantitative computed tomography (pQCT)
The pQCT scans were carried out with a pixel size of 0.1 mm and a
slice thickness of 0.5 mm using a StraTEC's XCT machine (Research SA
+, StraTEC Medizintechnik, GmbH, Pforzheim, Germany). A scout
view was performed prior to the actual scan to enable exact
positioning of the bone specimens. The region of interest selected
was similar to that used for μCT where the primary effect of
osteoporosis was expected to be signiﬁcant. Three types of volumetric
bone mineral density (vBMD) were obtained, i.e., mean BMD,
trabecular density (Tb.BMD) and cortical density (Ct.BMD). The
thresholds used for separating soft tissue from bone and sub-cortical
Fig. 1. The tibia specimen in the testing position. (A) μCT rendered image of rat tibia.
(B) Details of the three-point bending test consisting of the aluminum base and the
roller stamp.
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from trabecular bones were 280 mg/cm3 and 550 mg/cm3, respec-
tively. The mineral density measurements from pQCT were taken
from 5 adjacent slices within the region of interest for each tibia
sample, i.e., we measured BMD of 10 slices for each rat and reported
the mean values of each region of interest (Table 1).
Mechanical testing
A newly developed testing protocol was adopted for the three-
point bending test of metaphyseal tibiae [21]. A micro-testing
machine (Instron 5848, Norwood, MA, USA) with a measuring range
from 2 N to 1000 N at a precision of 0.2% of the load was used. The
speed of the feed motion was 5 mm/s with 5% strain rate and the
automatic switch-off pressure was set at 300 N. The experiment was
programmed to stop in case of a strength drop of N20 N or a linear
displacement of N2 mm to avoid shattering the tibial specimens.
Maximum load (Fmax), yield load (Fy) and stiffness (S) were recorded
using “Merlin” software. The yield load was determined by the 0.2%
offset method.
The tibia were thawed and continuously moistened with isotonic
saline solution during the test. Each tibia was placed with the three-
point contact on the aluminum base, consisting of an aluminum
block (30 mm wide, 14 mm high, 65 mm long) with the three
rounded edge free notches (1 mm deep; 2, 3, or 4 mm in diameter)
on top (Fig. 1B). The end of the dorsal proximal tibia (the two
condyles) was placed in one of the notches (a in Fig. 1B). Because of
its curved shape, the posterior distal diaphysis was rested on the
other side of base (b in Fig. 1B). During the breaking test, the
proximal tibia could not slip due to the notch on the base, but it
was able to lengthen along the diaphyseal axis. The tip of the stamp
consisted of an axle-led aluminum roller (8 mm high, 8 mm wide,
8 mm in diameter). A 2-mm-wide and 1-mm-deep circular notch
with rounded edges was located in the center of the roller (c in
Fig. 1B). The roller axle was ﬁxed in a U-shaped support, which was
connected to the micro tester by an aluminum stem. This
positioning of the tibia with the custom-made jig ensured its
stability during the three-point bending test [21].
The movable base was placed so that the distance between the
proximal end of the tibia (with epiphysis removed) and the center of
the roller stampwas 3 mm throughout the test to achieve a consistent
loading scenario. The stamp was driven down to the ventral
metaphysis of the tibia until the primary strength of 1 N was reached.
After a ﬁnal visual check of the correct tibia position, the breaking test
was started. The experiment was carried out without a priori
knowledge of the association between bones and animal groups.
Biomarkers of bone turnover
At week 0, 6 and 12, 300 μL of blood was collected from the lateral
tail vein after overnight fasting of the rats, 5 days after drug
administration. The serum was separated by centrifugation and
stored at −20 °C until analysis. Serum levels of bone formation
markers, procollagen type 1 N-terminal propeptide (P1NP), and bone
resorption markers, C-terminal cross-linked telopeptides of type I
collagen (CTX), were assessed using enzyme-linked immunosorbant
assay (Immunodiagnostic Systems Ltd, UK) [34,35] for control,
standard and duplicate tests.
Statistical analysis
One-way analysis of variance (ANOVA) was performed by time to
determine signiﬁcant difference between different groups for each
time point. Similarly, groupswere evaluated for signiﬁcant differences
over the entire period. Mixed-model and Bonferroni tests were
adopted. The analysis took into account the fact that two bones were
from the same rat sample, using rat as the random factor. With
preliminary data, t-test analysis was performed to calculate sample




At week 0 of ovariectomy surgery, there was no signiﬁcant
difference in average weight among all the testing groups. However,
at week 4, the average weight of OVX+VEH group was signiﬁcantly
higher than that of the SHAM group (338.8±18.1 and 294.3±16.6 g,
respectively, p=0.040). There was a general trend of longitudinal
increase in the body weight for all the groups, with OVX showing
signiﬁcant weight gain (p=0.009) by week 2 after surgery compared
to SHAM at week 8 (p=0.007). For treatment groups, weight gain for
animals given PTH, IBAN and combined treatment became obvious by
6 weeks (pb0.001), 4 weeks (p=0.006) and 2 weeks (p=0.038),
Table 1
Density changes of animal groups measured by pQCT. Group averages are represented as mean±SD.
Weeks after surgery
Groups 0 2 4 6 8 10 12
Mean BMD (mg/cm3) SHAM 631±16 743±14 743±20b 749±9b 786±70b 750±22b 780±11b
OVX+VEH 513±24 550±23a 584±93a 592±14a 573±4a 613±28a
OVX+PTH 617±25 647±38a 666±29a,b 664±24a,b
OVX+IBAN 632±9 718±49b 675±18a,b 764±29b
OVX+PTH+IBAN 653±63 701±39b 721±23b,c,d 782±13b,c
Tb.BMD (mg/cm3) SHAM 356±19 445±13b 430±9b 392±18b 456±18b 392±59b 427±9b
OVX+VEH 322±20a 273±27a 193±19a 200±13a 190±15a 179±15a
OVX+PTH 212±13a 231±20a 218±22a 217±20a,b
OVX+IBAN 255±47a 295±27a,b,c 281±34a,b,c 318±17a,b,c
OVX+PTH+IBAN 256±56a 268±50a,b 244±30a 272±25a,b,c,d
Ct.BMD (mg/cm3) SHAM 1043±3 1038±8 1061±28 1095±26 1090±13 1113±65 1120±22
OVX+VEH 1026±26 1064±24 1095±30 1110±33 1132±23 1154±16
OVX+PTH 1124±29 1156±21a,b 1174±13a 1171±16a
OVX+IBAN 1127±23 1161±30a,b 1153±15a,b 1160±31
OVX+PTH+IBAN 1132±19 1158±10a,b 1182±5a,b 1178±14a
Density changes by treatment groups measured using pQCT. Group averages are represented as mean±SD.
a Signiﬁcant difference from SHAM (pb0.05).
b Signiﬁcant difference from OVX+VEH (pb0.05).
c Signiﬁcant difference from OVX+PTH (pb0.01).
d Signiﬁcant difference form OVX+IBAN (pb0.01).
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respectively. At the end of study, the overall increase in average
weight was 29.3% (p=0.013), 54.9%, 46.7%, 52.3% and 69.5% (all
pb0.001) for SHAM, OVX+VEH, OVX+PTH, OVX+IBAN and OVX+
PTH+IBAN groups respectively.
Micro-computed tomography (μCT)
Three-dimensional rendering of the tibial metaphyseal region is
shown in Fig. 2 and the corresponding changes in the structural indices
determined from μCT scans are shown in Fig. 3. Within 6 to 8 weeks of
OVX surgery, trabecular bone micro-architecture of the OVX+VEH
group exhibited signiﬁcant difference from the SHAM group in all the
measured indices (BV/TV, Tb.Th, Tb.Sp, Tb.N, SMI and Tb.Po). This is in
agreement with previous reports [26,31] on the early detrimental
effects of estrogen deﬁciency on trabecular architecture of rats.
The anabolic effect of PTH on the trabecular architecture was
apparent. OVX+PTH showed signiﬁcant difference from the OVX+
VEH group in Tb.N and Tb.Sp after 4 weeks (+43.2% and −33.4%,
pb0.05) and 6 weeks (+61.3% and −40.5%, pb0.05) of treatment
respectively. After treatment for 8 weeks, OVX+PTH showed higher
Tb.N (+71.6%, p=0.024) and lower Tb.Sp (−31.8%, p=0.006), as
compared to the OVX+VEH group. We also observed signiﬁcant
increase in BV/TV (+81.8%, p=0.008), with a drop in Tb.Po (−16.2%,
p=0.008) compared to the OVX+VEH group at 6–8 weeks of PTH
treatment.
It has been shown that reduction in bone volume fraction (BV/
TV), loss of trabecular number (Tb.N) and increased trabecular
separation (Tb.Sp) were all prevented by ibandronate treatment in
an OVX rat model [36]. In this study, ibandronate's ability to
preserve bone microarchitecture was observed earlier than PTH.
After 2 weeks of treatment, OVX+IBAN exhibited signiﬁcant
difference from the OVX+VEH group in terms of BV/TV
(+82.9%, p=0.009), SMI (−53.5%, p=0.009), Tb.Po (−19.8%,
p=0.009) and Tb.N (+75.2%, p=0.016). Tb.Sp decreased signiﬁ-
cantly compared to OVX+VEH group after 4 weeks of treatment
(−38.8%, p=0.015). At the end of the study, BV/TV and Tb.N
increased (+78.2%, p=0.012) and (+76.9%, p=0.013), while SMI,
Tb.Po and Tb.Sp decreased (−21.4%, p=0.013), (−15.3%,
p=0.012) and (−50.4%, pb0.001) respectively as compared to
the OVX+VEH group.
The combined OVX+PTH+IBAN treatment showed a signiﬁcant
increase in BV/TV (+76.2%, p=0.01) and Tb.N (+67.5%, p=0.021) as
well as a signiﬁcantly lower Tb.Po (−18.2%, p=0.010) and SMI
(−41.1%, p=0.037), after 2 weeks of treatment.
Fig. 2. Visualization of bone loss in a transaction of the tibial metaphysis of an rat from each group at the time of surgery, and 2, 6, 10, and 12 weeks following surgery.
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Peripheral quantitative computed tomography (pQCT)
The mean BMD, trabecular density (Tb.BMD) and cortical density
(Ct.BMD) from pQCT scans for all the groups at different time points
are provided in Table 1. One-way ANOVA of the mean BMD of
different groups revealed a signiﬁcant difference between OVX+VEH
(−26.0%, pb0.001) and SHAM groups, starting from week 4 to the
end of experiment, revealing the successful establishment of our
ovariectomized rat model. From week 8 onwards, OVX+PTH+IBAN
(+18.4%, p=0.015) and OVX+IBAN (+21.3%, p=0.006) groups
showed a signiﬁcant difference from OVX+VEH group. At week 10,
mean BMD of all treatment groups, including OVX+PTH (+16.2%,
pb0.001) group, were signiﬁcantly higher than those of the OVX+
VEH group, which demonstrates the effectiveness of PTH and/or IBAN
treatments. Within the treatment groups, OVX+PTH+IBAN
(pb0.001) group had signiﬁcantly a higher mean BMD value than
OVX+PTH groups. At week 12, the ﬁnal week of our experiment, no
signiﬁcant difference was found among OVX+PTH+IBAN, OVX+
IBAN and SHAM groups in terms of mean BMD.
OVX+VEH exhibited a signiﬁcantly lower Tb.BMD (−27.6%,
p=0.002) than SHAM from week 2 onwards. The OVX+IBAN and
OVX+PTH+IBAN groups showed signiﬁcantly higher Tb.BMD
(+47.5%, pb0.001 and +34.0%, p=0.011) than OVX+VEH group
from week 8. At the end of experiment (week 12), all three treatment
groups showed signiﬁcantly higher Tb.BMD (pb0.05) with the
OVX+IBAN group showing the highest value among all treatment
groups. We also observed a plateau in Tb.BMD for OVX+VEH and
OVX+PTH from week 6 onwards.
The Ct.BMD of all the rat groups showed an increasing trend with
time, indicating the continual cortical bone growth. Ct.BMD of the
treatment groups (OVX+IBAN, OVX+PTH, OVX+PTH+IBAN) was
signiﬁcantly higher (pb0.05) than OVX+VEH at week 8. However,
after week 8, the Ct.BMD of OVX+IBAN reached a plateauwhereas Ct.
BMD of OVX+PTH and OVX+PTH+IBAN groups reached the
plateau after week 10.
Besides BMD measurement, we have conducted strength–strain
indices with respect to Y axis (SSIy) to assess the difference in
mechanical property of OVX+IBAN+PTH group which showed
the similar BMD values to the OVX+IBAN group [37]. The SSI is
related to both geometrical properties and cortical density [38,39].
At the 12th week, SSIy value of all groups are presented as follow:
SHAM=6.10±0.53 mm3, OVX+VEH=4.44±0.59 mm3, OVX+
PTH=5.43±0.88 mm3, OVX+IBAN=5.70±0.38 mm3, OVX+
PTH+IBAN=7.36±0.79 mm3. The SSIy of OVX+PTH+IBAN
group was signiﬁcantly higher than IBAN (p=0.007), PTH
(p=0.001) and OVX (pb0.001) groups. The percentage increase
from OVX+VEH in the OVX+PTH+IBAN group (66%) was greater
than the sum of the effects of PTH alone (22%) and IBAN alone
(28%) in SSIy. As shown in Fig. 4, the signiﬁcance and trend are in
accordance with Fmax results (R2=0.8033, pb0.001).
Fig. 3. Changes in trabecular morphology measured by microCT. Top row: bone volume fraction (BV/TV), structure model index(SMI), and trabecular porosity(Tb.Po). Bottom row:
trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), and trabecular number (Tb.N).
Fig. 4. Positive linear correlation between maximum load (Fmax) and strength–strain
index to the y axis (SSIy).
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Mechanical testing
The results of maximum load (Fmax), yield load (Fy) and
stiffness (S) of different groups from three-point bending tests
are provided in Table 2. Due to the growth of the rats involved in
this study, Fmax of SHAM group increased from 61.2±21.7 N in
week 0 to 104.0±11.0 N at week 12 (+69.9%). However, there
was no signiﬁcant change in the OVX+VEH group from week 2
(49.4±11.8 N) to week 12 (48.9±12.1 N). There was a signiﬁcant
difference between SHAM and OVX+VEH groups from the second
week after surgery, indicating the development of osteoporosis.
Among the treatment groups, in weeks 8 and 12, Fmax values of
OVX+PTH+IBAN group are signiﬁcantly higher than those of
either the OVX+IBAN or the OVX+PTH group. However, in week
10, the OVX+PTH+IBAN group only shows signiﬁcantly higher
Fmax than the OVX+PTH group. At week 12, the percentage
increase from OVX+VEH in the OVX+PTH+IBAN group (168%)
was greater than the sum of the effects of PTH alone (59%) and
IBAN alone (77%) in Fmax.
Therewasa signiﬁcantdifference in FybetweenSHAMandOVX+VEH
groups in week 12 (p=0.048). Fy in the OVX+VEH group decreased by
18.2% fromthe surgery toweek12,while a sharp increasewasobserved in
the OVX+PTH, OVX+IBAN and OVX+PTH+IBAN groups at week 12
(36.6%, 67.7% and 126.8% respectively).
From the day of surgery to the end of 12th week, stiffness in
OVX+VEH has decreased by 38.9%. On the other hand, in the SHAM
group, stiffness was relatively stable, from 184.8±19.4 N/mm to
206.7±31.2 N/mm (Table 2). From the 10th week, signiﬁcant
difference was seen between the SHAM and OVX groups
(p=0.045). At the end of the experiment at week 12, within the
three treatment groups the only observed signiﬁcant difference was
the OVX+PTH+IBAN group compared to OVX+VEH (p=0.010).
Biomarkers of bone turnover
The serum levels of bone formation (P1NP) and bone resorption
(CTX) biomarkers at 0, 6 and 12 weeks of different rat groups are
provided (Table 3).
At week 0, the serum P1NP concentration of different groups did
not show any signiﬁcant difference. However, at the end of week 12,
OVX+PTH+IBAN and OVX+PTH showed signiﬁcantly higher
(pb0.001) levels of P1NP than the rest of the groups. Moreover,
OVX+PTH+IBAN showed 71% signiﬁcant higher concentration of
P1NP than the OVX+PTH group (pb0.001).
At week 0, the serum CTX levels of different groups did not show
any signiﬁcant difference. At the end of week 12, a serum CTX level of
the OVX+VEH group was 113.2% (pb0.05) higher than that of the
SHAM group, indicating higher bone resorption in the OVX group than
in the SHAMgroup. OVX+PTH did not show any signiﬁcant difference
from the OVX+VEH group. OVX+IBAN and OVX+PTH+IBAN
showed a signiﬁcant decrease in the serum CTX levels as compared to
the OVX+VEH group, suggesting that ibandronate alone or its
concurrent administration with PTH decreases bone resorption.
Discussion
This study investigated the effects of ovariectomy-induced
osteoporosis and the efﬁcacy of the combination therapy of anabolic
(PTH) and anti-resorptive (ibandronate) drugs in terms of morpho-
logical and biomechanical analyses. By using the OVX rat model [40],
the changes in bone quality and the efﬁcacy of concurrent treatments
were assessed through μCT, pQCT, biomarkers and three-point
bending tests. The SHAM group served as a negative control to
Table 2
Mechanical property changes of animal groups measured by 3-point bending test. Group averages are represented as mean±SD.
Weeks after surgery
Groups 0 2 4 6 8 10 12
Fmax (N) SHAM 61.2±21.7 92.7±31.9b 91.8±19.6b 101.5±5.7b 117.0±25.3b 115.5±6.8b 104.0±11.0b
OVX+VEH 49.4±11.8a 44.2±9.0a 59.1±15.3a 50.5±11.9a 63.1±12.5 48.9±12.1a
OVX+PTH 64.4±6.7a 57.3±12.0a 67.4±10.1 77.9±17.6
OVX+IBAN 65.0±13.0a 85.3±3.6b 80.3±9.6 86.4±17.4b
OVX+PTH+IBAN 81.8±3.4 121.5±11.5b,c,d 107.1±19.2b,c 131.1±18.1b,c,d
Fy (N) SHAM 42.4±20.4 42.2±14.5 44.7±9.7 70.7±7.8 72.2±7.1b 75.7±5.8 72.3±14.3b
OVX+VEH 41.9±20.8 30.3±14.2 48.1±10.5 33.3±13.4a 30.8±7.6 34.7±7.0a
OVX+PTH 38.8±6.7a 31.1±4.8 43.8±10.4 47.4±9.8
OVX+IBAN 41.7±1.6a 54.6±11.5 51.8±17.5 58.2±20.8
OVX+PTH+IBAN 58.5±15.4 75.4±15.5b 58.8±15.1 78.7±23.1b
S (N/mm) SHAM 184.8±19.4 167.1±30.9 163.7±33.0 190.3±11.6 209.0±30.9 201.1±19.5b 206.7±31.2b
OVX+VEH 111.7±35.7 118.4±50.3 112.7±6.8 166.6±30.7 141.8±12.3a 112.8±14.3a
OVX+PTH 163.9±47.7 153.4±43.2 172.1±16.1 176.6±26.0
OVX+IBAN 158.1±41.2 189.0±25.9 190.3±17.1 180.0±56.0
OVX+PTH+IBAN 147.8±10.1 253.6±47.3b,c 187.5±15.2 214.0±19.2b
Mechanical property changes by treatment groups measured using 3-point bending test. Group averages are represented as mean±SD.
a Signiﬁcant difference from SHAM (pb0.05).
b Signiﬁcant difference from OVX+VEH (pb0.05).
c Signiﬁcant difference from OVX+PTH (pb0.05).
d Signiﬁcant difference from OVX+IBAN (pb0.05).
Table 3
Serum levels of bone formation (P1NP) and resorption (CTX) markers. Average
concentration is expressed as mean±SD.
Week(s) after surgery
Groups 0 6 12
P1NP (μg/L) SHAM 19.9±11.6 14.4±7.2 7.8±0.1
OVX+VEH 17.3±7.9 7.8±1.1 7.6±0.2
OVX+PTH 19.6±11.9 10.3±0.7 28.6±3.6a,b
OVX+IBAN 13.3±2.1 9.3±2.3 6.1±0.3
OVX+PTH+IBAN 21.6±3.1 12.9±1.8 48.9±4.0a,b,c,d
CTX (μg/L) SHAM 21.4±0.1 28.3±5.0 15.2±2.8b
OVX+VEH 21.6±3.0 43.2±13.9 32.4±4.1a
OVX+PTH 23.3±9.0 36.6±7.4 41.4±1.8a
OVX+IBAN 20.5±3.8 29.8±11.0 14.3±4.6b,c
OVX+PTH+IBAN 26.2±0.2 14.1±1.6 17.5±3.6b,c
Serum levels of bone formation (P1NP) and resorption (CTX) markers. Average
concentrations are expressed as mean±SD.
a Signiﬁcant difference from SHAM (pb0.05).
b Signiﬁcant difference from OVX+VEH (pb0.05).
c Signiﬁcant difference from OVX+PTH (pb0.01).
d Signiﬁcant difference from OVX+IBAN (pb0.01).
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illustrate normal bone growth over the course of the experiment. The
OVX+VEH group was a positive control group to study changes
occurring during the development of osteoporotic condition following
the ovariectomy and to compare the effect of various treatments.
Differences between OVX and SHAM have been well-characterized
from previous studies using micro-CT [29,31,36,40,41] and three-
point bending tests [21,41]. The effects of individual treatments such
as anti-resorptive treatments: tiludronate [31], ibandronate [36] and
raloxifene [41] and estrogen replacements: estradiol benzoate [41]
and cenestin A [42], have also been extensively studied. Fewer
animals (2 animals per time point) were allocated to the OVX and
SHAM group in this study due to the existing results in those groups.
In this study, relatively young rats (12 weeks old) were used for OVX
surgery. There are other studies which successfully used 3-month-old
rats to investigate the effects of estradiol, testosterone and raloxifene
in fracture healing during early osteoporosis [21,41]. Moreover, the
effect of vibrational stimulation to prevent bone loss in the OVXmodel
was thoroughly investigated using 3-month-old rats [43–45]. Unlike
the rabbit osteoporosis model [46], the skeletons of aged rats do not
achieve full skeletal maturity and have very low rates of remodeling in
the cortical bone. Therefore, the trabecula-rich VOI in the proximal
metaphysis of rat tibiae is appropriate to study the efﬁcacy of the anti-
resorptive and/or anabolic drugs in OVX rat model.
The most signiﬁcant reduction occurred in bone volume fraction
(BV/TV), trabecular thickness (Tb.Th) and trabecular number (Tb.N)
during the ﬁrst 6–8 weeks after OVX surgery. The trabecular struts
became more rod-like and the bone material within the VOI became
signiﬁcantly porous. These results are consistent with previous
studies which reported that irreversible micro-architectural changes
happen within the ﬁrst 8 to 12 weeks after the ovariectomy
[26,29,42]. BV/TV for the SHAM group used in this study was
comparatively higher than in previous studies [26,29,42] due to the
fact that we used 12-week-old mature virgin rats as compared to 6- to
8-month-old retired breeders. We observed 57% reduction in BV/TV
while previous studies reported a 30–40% reduction within the same
period of 8 weeks post-ovariectomy [26,42]. Bone loss resulting from
estrogen deﬁciency in younger rats is proportionally more drastic,
mainly because younger rats have denser trabecular bone at the
beginning. Plateaus were observed from 8 weeks onwards for
structure model index (SMI), trabecular thickness (Tb.Th), trabecular
number (Tb.N) and trabecular density (Tb.BMD) for OVX, as
previously described by Campbell et al. [26]. The leveling off of
microarchitectural changes was observed even in the treatment
groups. Thus, drastic structural changes following estrogen deﬁciency
and the leveling off in microarchitectural indices illustrate the
importance of early treatment in osteoporosis in order to prevent
further deterioration in bone.
Ibandronate inhibits bone resorption and formation by reducing
the bone turnover rate [14,47], which helps to protect the trabecular
microstructure from the deleterious effects of bone resorption.
Between 2 and 4 weeks after administration, the anti-resorptive
effect of ibandronate was apparent in the higher BV/TV and Tb.N and
lower SMI, Tb.Sp and Tb.Po as compared to OVX+VEH group (Fig. 3).
The beneﬁcial effect of ibandronate was also observed from pQCT,
which showed a signiﬁcant increase in Tb.BMD after 4 weeks of
administration (Table 1). Smith et al. also reported a similar effect of
ibandronate in preventing bone loss andmaintaining bone strength in
ovariectomized cynomolgus monkeys [48]. Even though the positive
effects of ibandronate could be observed as early as 2–4 weeks after
administration, the duration was limited as indicated in the plateau of
μCT and pQCT indices.
PTH stimulates bone formation and also bone resorption [49],
effectively increasing bone remodeling rate. The net result can
produce a catabolic or anabolic effect on trabecular bone depending
on dosage and frequency of administration [49,50]. The comparatively
higher PTH-to-ibandronate ratio and intermittent PTH administration
used in our study exerted a net anabolic effect on BV/TV, Tb.Sp and Tb.
Po from the 10th week after OVX surgery. Effects of ibandronate on
the structural indices were observed as early as the 2ndweek after the
administration of the drug. The fact that the effect of PTH was
signiﬁcant only after 6 weeks in rats suggests that ibandronate was
more effective at preventing the early deterioration of trabecular bone
than PTH at similar dosage.
Previous studies using alendronate have shown that it may reduce
PTH's anabolic effects on bone tissues [5,16,17]. In our study of using
the combined PTH and ibandronate treatment, however, signiﬁcant
increase in BV/TV and Tb.N while achieving lower SMI and Tb.Po was
observed from the 2ndweek after treatment initiation as compared to
individual treatments. The non-blocking effect of the concurrent
treatments could also be observed in the mean BMD of the pQCT
results (Table 1). This suggests no reduction in PTH's anabolic effects
when combined with ibandronate administration.
The results from three-point bending tests were compared to
pQCT and μCT analysis to evaluate the mechanical property change of
the rat tibiae, corresponding to those of structural changes. Tibiae
treated with either drug or their combination had signiﬁcantly higher
Fmax than OVX+VEH rats. Among treatment groups, a signiﬁcant
improvement on Fmax was observed in the OVX+PTH+IBAN group
at the end of the study. This means that the combined treatment
would allow the bone to withstand higher load before fracturing
compared to monotherapy. This phenomenon is consistent with the
higher BMD and Ct.BMD in the combined drug treated group as
obtained from pQCT. Large standard deviation of Fy in the OVX+
PTH+IBAN group resulted in the loss of statistical signiﬁcance
when compared to other treatment groups. This made it difﬁcult to
draw a conclusion on early stage microfracture in response to each
individual treatment. However, the combined treatment group
showed signiﬁcantly higher stiffness than the vehicle treated
group, with stiffness approaching those of the SHAM group.
From the biomarker results, we could see that OVX+PTH group
had signiﬁcantly higher (pb0.001) levels of P1NP than OVX+VEH
group whereas CTX levels of OVX+PTH did not show any signiﬁcant
difference from OVX+VEH group. This shows that PTH treatment
resulted in higher bone formation, but had no inﬂuence on bone
resorption. Meanwhile, OVX+IBAN group had signiﬁcantly lower
(p=0.015) levels of CTX compared to the OVX+VEH group but the
P1NP levels of OVX+IBAN did not show any signiﬁcant difference
from OVX+VEH group. This shows that ibandronate treatment
resulted in reduced levels of bone resorption, but had no inﬂuence
on bone formation. Overall, the mono-treatment OVX+PTH group
showed only increased bone formation and the OVX+IBAN group
showed only decreased bone resorption, as is consistentwith previous
studies [51,52]. On the other hand, the combined treatment group
(OVX+PTH+IBAN) showed signiﬁcantly higher (pb0.001) levels of
P1NP as well as lower (p=0.040) levels of CTX as compared to
OVX+VEH group. This shows that the concurrent treatment has an
added advantage on bone mass as it results in the increase in bone
formation as well as a signiﬁcant decrease in bone resorption.
Interestingly, the CTX levels of OVX+IBAN+PTH group did not
signiﬁcantly differ from OVX+IBAN, whereas the P1NP levels of
OVX+IBAN+PTH were signiﬁcantly higher (pb0.001) than the
OVX+PTH group. This shows that PTH has very little or no effect
on the action of ibandronate, whereas concurrent administration of
ibandronate has a positive effect of inducing the action of PTH,
thereby increasing bone formation.
As a counteradditive effect on concurrent administration of both
anabolic and anti-resorptive drugs was shown in previous studies
[5,16,17], a partial positive additive effect was observed in Fmax, SSIy
and P1NP results in this study. To our knowledge, this is the ﬁrst study
to assess concurrent administration of ibandronate (third generation
bisphosphonates) and PTH in an OVX rat model. Most of the previous
studies that analyzed the additive effect of the anabolic and anti-
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resorptive treatments used the second generation bisphosphonates
(alendronate) along with PTH [5,6,15–19]. While other bispho-
sphonates require frequent administration to maintain their beneﬁ-
cial effects, Bauss et al. [28] have shown that effect of ibandronate is
accumulative and independent on the frequency of drug administra-
tion. The truncated parathyroid hormone (1–34) used in this study
was different from full intact parathyroid hormone (1–84). It is
speculated that the presence or the absence of the C-terminal region
of the PTH molecule can affect the expression of a biological response
[53]. Since there is no previous study of using PTH and ibandronate on
SD rats to follow the used dosage, thus, based on previous study on the
dose-dependent effect of PTH (SD rats) [27] and ibandronate (Wistar
rats) [28], we adopted a relatively high dosage ratio of PTH-to-
ibandronate via weekly administration compared to the prevalent
therapies for the OVXmodel [18,54]. We believe the effect of a drug to
those two rats should be quite similar in physical characteristics,
which facilitated our decision of choosing drug dosage based on their
body weight. The use of weekly low dosages of both PTH and
ibandronate (with higher PTH-to-ibandronate ratio) still provided
beneﬁts while avoiding negative consequences associatedwith higher
dosages [55,56].
Despite encouraging results, higher dosage and extended
duration of exogenous PTH (1–34) treatment have been reported
to produce undesirable side effects [55,56]. Sato et al. reported that
a daily treatment of only 8 μg/kg PTH (1–34) for 1 year in OVX rats
can result in an 11% increase in cortical bone brittleness [56]. Also,
PTH (1–34) therapy has been linked with hypercalcemia both in
animals and in clinical studies [57]. Headaches, nausea and back
pain were reported with clinical PTH (1–34) therapy [57]. Thus, we
reduced the PTH (1–34) dosing frequency from daily to weekly as
a means of circumventing some of these adverse effects. The PTH
(1–34) dosage and frequency we adopted are in accordance with a
comparative study by Gittens et al. [27]. The comparison between
the data in their experiment and the current study suggested that
these low doses, 28–40 μg/kg over 4 weeks, may be close to the
threshold for effective dosage for bone mass accretion in the OVX
rat model. Also, it has been reported that weekly administration of
PTH increases bone mass as much as daily administration of PTH
[58].
Additionally, the high dosage used in previous studies is not
clinically relevant. The clinical dose of PTH (1–34) used for
osteoporosis therapy is 20 μg/day [17,59]. In rats, PTH (1–34) doses
of 5 μg/kg/day result in 3 times the systemic exposure seen with
20 μg/day in patients [60]. However, prior fracture studies in rats have
used doses of PTH(1–34) as high as 200 μg/kg/day [61], calling into
question the clinical relevance of the dosage used. These data
underscore the importance of conducting clinical studies to evaluate
the optimized dosage of PTH in bone regeneration [59].
The mean BMD results were in agreement with the three-point
bending results in terms of Fmax, Fy and S, suggesting that BMD
measurements can still be used to predict mechanical properties of
bone. The lack of sufﬁcient statistical signiﬁcance in our three-point
bending test may be due to the following reasons. The rats used in this
study were considerably young and their skeleton still growing. Also,
three different types of fractures (the metaphyseal oblique fracture,
the Y-fracture, and the condyle fracture) observed by Stürmer et al.
[21] may exist in all animal groups, but were not taken into account in
this study due to limited sample size.
Besides BMD measurement, we have conducted strength–strain
indices (SSI) calculation to understand the combined treatment effect
of OVX+IBAN+PTH group which showed the similar BMD values to
OVX+IBAN group. Since SSI is related to both geometrical properties
and cortical density, the axial SSIy predicts the bending strength with
respect to the Y axis (the longitudinal axis of rat tibiae). At the 12th
week of study, the SSIy of OVX+PTH+IBAN group was signiﬁcantly
higher than IBAN (p=0.007), PTH (p=0.001) and OVX (pb0.001)
groups. The percentage increase from OVX+VEH in the OVX+PTH+
IBAN group was greater than the sum of the effects of PTH alone and
IBAN alone for SSIy and Fmax, indicating an additive effect. As shown in
Fig. 4, the signiﬁcance and trend are in accordance with Fmax results
(R2=0.8033, pb0.001). A recent study shows that SSIy presents a
signiﬁcantly positive correlation with maximum load with a correla-
tion value R=0.846 (pb0.001) [37]. Since SSIy served as a good
predictor of Fmax, the SSIy values from this study could serve as an
explanation for the discrepancy between BMD andmechanical testing
results.
As discussed, we have conducted a pilot study with a relatively
low dosage and weekly administration of ibandronate and PTH. A
higher ratio of anabolic to anti-resorptive agent is less likely to
inhibit the bone formation function by PTH, which could account for
the lack of blocking effect by ibandronate used in this study. It also
provides a possible explanation of why an anti-resorptive agent
(ibandronate) is more effective than an anabolic agent (PTH) on
BMD and mechanical properties. We believe the partial beneﬁcial
effect is attributed to the proper drug dosage and ratio so that the
effect of PTH on bone density can be optimized when a potent anti-
resorptive agent is used either concurrently or alternatively. In
previous rodent studies, the effect of concurrent treatment of PTH
and bisphosphonate was additive at drug ratios of 1:0.3 [18] and
1:0.2 [54]. On the other hand, negative/blocking effects from
alendronate occurred at dose ratios of 1:100 [5] and 1:250 [17] in
clinical trials. In this study, we used a PTH-to-ibandronate ratio of
1:0.7 according to tests done by previous studies [14,27,28]. A
threshold ratio of anabolic to anti-resorptive agents would be
postulated in this OVX model. If the dosage of bisphosphonate went
beyond the threshold, no beneﬁcial effect would be observed. Below
this threshold ratio, an increase of PTH dosage might lead to an
increase in beneﬁcial effect correspondingly [62]. Series of ratio
dependency experiments and histomorphometric studies would be
conducted subsequently to better illustrate the mechanism of this
effects. Apart from dose and ratio, other factors such as rodent
appendicular bone effect, nature of drug time course (daily, cyclic,
alternation therapies, etc.) could also be possible factors that affect
the results of this combination therapy.
Conclusion
Compared to the previous studies which showed impedance from
bisphosphonates in combination therapy with PTH, our study
suggested that ibandronate does not block the anabolic effects of
PTH in ovariectomized rat tibiae. Maximum load, strength–strain
indices and bone formation serum markers of OVX+PTH+IBAN
group are signiﬁcantly higher compared to bothmonotherapy groups.
The effect may be attributed to the proper ratio of anabolic and anti-
resorptive drugs combined with the appropriate course of treatment.
Further exploration of these ﬁndings would allow us to optimize the
ratio between PTH and ibandronate and maximize the beneﬁcial
effects of the concurrent administration of the two drugs in the
treatment of osteoporosis.
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